

ADOPTED: 4 May 2023

doi: 10.2903/j.efsa.2023.8028

## Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infectious pancreatic necrosis (IPN)

EFSA Panel on Animal Health and Welfare (AHAW),  
Søren Saxmose Nielsen, Julio Alvarez, Paolo Calistri, Elisabetta Canali, Julian Ashley Drewe,  
Bruno Garin-Bastuji, José Luis Gonzales Rojas, Christian Gortázar, Mette S Herskin,  
Virginie Michel, Miguel Ángel Miranda, Barbara Padalino, Paolo Pasquali,  
Helen Clare Roberts, Hans Spoolder, Karl Ståhl, Antonio Velarde, Arvo Viltrop,  
Christoph Winckler, James Bron, Niels Jorgen Olesen, Hilde Sindre, David Stone,  
Niccolò Vendramin, Sotiria-Eleni Antoniou, Lisa Kohnle, Alexandra Papanikolaou,  
Anna Eleonora Karagianni and Dominique Joseph Bicot

### Abstract

Infectious pancreatic necrosis (IPN) was assessed according to the criteria of the Animal Health Law (AHL), in particular, the criteria of Article 7 on disease profile and impacts, Article 5 on its eligibility to be listed, Annex IV for its categorisation according to disease prevention and control rules as in Article 9, and Article 8 for listing animal species related to IPN. The assessment was performed following a methodology previously published. The outcome reported is the median of the probability ranges provided by the experts, which indicates whether each criterion is fulfilled (lower bound  $\geq 66\%$ ) or not (upper bound  $\leq 33\%$ ), or whether there is uncertainty about fulfilment. Reasoning points are reported for criteria with an uncertain outcome. According to the assessment here performed, it is uncertain whether IPN can be considered eligible to be listed for Union intervention according to Article 5 of the AHL (50–90% probability). According to the criteria in Annex IV, for the purpose of categorisation related to the level of prevention and control as in Article 9 of the AHL, the AHAW Panel concluded that IPN does not meet the criteria in Section 1 (Category A; 0–1% probability of meeting the criteria) and it is uncertain whether it meets the criteria in Sections 2, 3, 4 and 5 (Categories B, C, D and E; 33–66%, 33–66%, 50–90% and 50–99% probability of meeting the criteria, respectively). The animal species to be listed for IPN according to Article 8 criteria are provided.

© 2023 European Food Safety Authority. *EFSA Journal* published by Wiley-VCH GmbH on behalf of European Food Safety Authority.

**Keywords:** aquatic animals, Animal Health Law, infectious pancreatic necrosis, listing, categorisation, impact

**Requestor:** European Commission

**Question number:** EFSA-Q-2022-00551

**Correspondence:** [ahaw@efsa.europa.eu](mailto:ahaw@efsa.europa.eu)

**Panel members:** Søren Saxmose Nielsen, Julio Alvarez, Paolo Calistri, Elisabetta Canali, Julian Ashley Drewe, Bruno Garin-Bastuji, José Luis Gonzales Rojas, Christian Gortázar, Mette S Herskin, Virginie Michel, Miguel Ángel Miranda, Barbara Padalino, Paolo Pasquali (active until 5 April 2023), Helen Clare Roberts, Hans Spoolder, Karl Ståhl, Antonio Velarde, Arvo Viltrop, Christoph Winckler and Dominique Joseph Bicout

**Declarations of interest:** If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact [interestmanagement@efsa.europa.eu](mailto:interestmanagement@efsa.europa.eu).

**Acknowledgements:** The AHAW Panel wishes to thank P95 (EFSA contractor PO/EFSA/BIOHAW/2022/03) for drafting the fact sheet on the disease profile according to the criteria of Article 7 of the Animal Health Law and related parameters (Section 3.1).

**Suggested citation:** EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), Nielsen SS, Alvarez J, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Rojas JLG, Gortázar C, Herskin MS, Michel V, Chueca MAM, Padalino B, Pasquali P, Roberts HC, Spoolder H, Ståhl K, Velarde A, Viltrop A, Winckler C, Bron J, Olesen NJ, Sindre H, Stone D, Vendramin N, Antoniou S-E, Kohnle L, Papanikolaou A, Karagianni AE and Bicout DJ, 2023. Scientific Opinion on the assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infectious pancreatic necrosis (IPN). *EFSA Journal* 2023;21(6):8028, 88 pp. <https://doi.org/10.2903/j.efsa.2023.8028>

**ISSN:** 1831-4732

© 2023 European Food Safety Authority. *EFSA Journal* published by Wiley-VCH GmbH on behalf of European Food Safety Authority.

This is an open access article under the terms of the [Creative Commons Attribution-NoDerivs](https://creativecommons.org/licenses/by/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.



The EFSA Journal is a publication of the European Food Safety Authority, a European agency funded by the European Union.



## Table of contents

Abstract.....	1
1. Introduction.....	5
1.1. Background and terms of reference as provided by the requestor.....	5
1.1.1. Background.....	5
1.1.2. Disease specific information.....	5
1.1.3. Terms of Reference.....	6
1.2. Interpretation of the terms of reference (if appropriate).....	6
2. Data and methodologies.....	7
3. Assessment.....	8
3.1. Assessment according to article 7 criteria.....	8
3.1.1. Article 7(a) disease profile.....	8
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease.....	9
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations.....	13
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease.....	15
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance.....	15
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the environment.....	15
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals, and, when relevant, between animals and humans.....	16
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the union, and, where the disease is not present in the union, the risk of its introduction into the union.....	17
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools.....	19
3.1.2. Article 7(b) The impact of the disease.....	20
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture production and other parts of the economy.....	20
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health.....	21
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare.....	21
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment.....	21
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use in bioterrorism.....	22
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following disease prevention and control measures.....	22
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities.....	22
3.1.4.2. Article 7(d)(ii) Vaccination.....	23
3.1.4.3. Article 7(d)(iii) Medical treatments.....	25
3.1.4.4. Article 7(d)(iv) Biosecurity measures.....	25
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products.....	26
3.1.4.6. Article 7(d)(vi) Killing of animals.....	26
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products.....	27
3.1.4.8. Article 7(d)(viii) Selective breeding; genetic resistance to infection.....	27
3.1.5. Article 7(e) The impact of disease prevention and control measures.....	28
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy as a whole.....	28
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control measures.....	29
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals.....	30
3.1.5.4. Article 7(e)(iv) The environment and biodiversity.....	30
3.2. Assessment of infectious pancreatic necrosis according to Article 5 criteria of AHL on its eligibility to be listed.....	30
3.2.1. Detailed outcome on Article 5 criteria.....	30
3.2.2. Reasoning for uncertain outcome on Article 5 criteria.....	32
3.2.3. Overall outcome on Article 5 criteria.....	32
3.3. Assessment infectious pancreatic necrosis according to criteria in Annex IV for the purpose of categorisation as in Article 9 of the AHL.....	33
3.3.1. Detailed outcome on Category A criteria.....	33
3.3.1.1. Reasoning for uncertain outcome on Category A criteria.....	34
3.3.2. Detailed outcome on Category B criteria.....	35
3.3.2.1. Reasoning for uncertain outcome on Category B criteria.....	36
3.3.3. Detailed outcome on Category C criteria.....	37
3.3.3.1. Reasoning for uncertain outcome on Category C criteria.....	38
3.3.4. Detailed outcome on Category D criteria.....	39
3.3.5. Detailed outcome on Category E criteria (Table 14).....	39
3.3.6. Overall outcome on criteria in Annex IV for the purpose of categorisation as in Article 9.....	39
3.4. Assessment of infectious pancreatic necrosis according to Article 8 criteria of the AHL.....	41
4. Conclusions.....	44

References..... 44  
Abbreviations..... 52  
Appendix A – Expert judgement plotted by question..... 53  
Appendix B – Expert judgement: medians for all questions..... 88



## 1. Introduction

### 1.1. Background and terms of reference as provided by the requestor

#### 1.1.1. Background

Article 5 of the Regulation (EU) 2016/429 of the European Parliament and of the Council on transmissible animal diseases (Animal Health Law (AHL))<sup>1</sup>, provides for the list of diseases to which the rules set out in the AHL apply. These rules include the assessment provided for in Article 7 and the categorisation of those diseases as provided for in Article 9 of that Regulation.

In addition to the list of five significant diseases laid down in Article 5(1) of the AHL, a further list of animal diseases is set out in Annex II to that Regulation, which may be amended by means of a delegated regulation.

In addition, there are other transmissible diseases of aquatic animals for which certain control or trade measures apply today in accordance with Article 226(3) of the AHL, and which are not included in Annex II to the AHL.

Details of those diseases and the Member States or parts thereof which are regarded as being free from one or more of them, or which are subject to an eradication programme, are set out in Annexes I and II to Commission Implementing Decision (EU) 2021/260<sup>2</sup>. The aquatic species which are considered to be susceptible to those diseases are set out in Annex III to that Implementing Decision.

At least some of these diseases may fulfil the criteria to be listed in accordance with Article 5(3), following assessment in accordance with Article 7. In cases where listing is justified, these diseases should also be categorised in accordance with Article 9(1) and Annex IV of the AHL, and species, or groups of animal species, that are either susceptible to the diseases in question or have the capability to act as vectors, should be listed in accordance with Article 8(3) of the AHL.

The Commission, therefore, requires scientific advice concerning the following diseases, within the framework described above:

- Spring viraemia of carp (SVC);
- Bacterial kidney disease (BKD);
- Infectious pancreatic necrosis (IPN);
- Infection with *Gyrodactylus salaris* (GS);
- Infection with salmonid alphavirus (SAV).

#### 1.1.2. Disease specific information

##### (a) Spring viraemia of carp (SVC)

Specific international trade standards for infection with spring viraemia of carp virus are provided for in Chapter 10.9. of WOAHP (formerly OIE) Aquatic Animal Health Code (the WOAHP (formerly OIE) Code), as well as in Chapter 2.3.9. of the WOAHP (formerly OIE) Manual of Diagnostic for Aquatic Animals (the WOAHP (formerly OIE) Manual).

In the existing EU legislative acts, spring viraemia of carp is referred to in Commission Implementing Decision (EU) 2021/260 of 11 February 2021, approving national measures designed to limit the impact of certain diseases of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU.

##### (b) Bacterial kidney disease (BKD)

Specific international trade standards for bacterial kidney disease are not provided in the Aquatic Animal Health Code (the WOAHP (formerly OIE) Code) or in the WOAHP (formerly OIE) Manual of Diagnostic for Aquatic Animals (the WOAHP (formerly OIE) Manual).

Bacterial kidney disease is however, referred to in Commission Implementing Decision (EU) 2021/260 of 11 February 2021, approving national measures designed to limit the impact of certain diseases

<sup>1</sup> Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health ('Animal Health Law')(OJ L 84, 31.3.2016, p. 1).

<sup>2</sup> Commission Implementing Decision (EU) 2021/260 of 11 February 2021 approving national measures designed to limit the impact of certain diseases of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU (OJ L 59, 19.2.2021, pp. 1–9).

of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU.

### (c) Infectious pancreatic necrosis (IPN)

Specific international trade standards for infectious pancreatic necrosis are not provided in the Aquatic Animal Health Code (the WOA (formerly OIE) Code) or in the WOA (formerly OIE) Manual of Diagnostic for Aquatic Animals (the WOA (formerly OIE) Manual).

Infectious pancreatic necrosis is however, referred to in Commission Implementing Decision (EU) 2021/260 of 11 February 2021, approving national measures designed to limit the impact of certain diseases of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU.

### (d) Infection with *Gyrodactylus salaris* (GS)

Specific international trade standards for infection with *Gyrodactylus salaris* are provided for in Chapter 10.3. of the WOA (formerly OIE) Aquatic Animal Health Code (the WOA (formerly OIE) Code), as well as in Chapter 2.3.3. of the WOA (formerly OIE) Manual of Diagnostic for Aquatic Animals (the WOA (formerly OIE) Manual).

In the existing EU legislative acts, infection with *Gyrodactylus salaris* is referred to in Commission Implementing Decision (EU) 2021/260 of 11 February 2021, approving national measures designed to limit the impact of certain diseases of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU.

### (e) Infection with salmonid alphavirus (SAV)

Specific international trade standards for infection with salmonid alphavirus are provided for in Chapter 10.5. of the WOA (formerly OIE) Aquatic Animal Health Code (the WOA (formerly OIE) Code), as well as in Chapter 2.3.8. of the WOA (formerly OIE) Manual of Diagnostic for Aquatic Animals (the WOA (formerly OIE) Manual).

In the existing EU legislative acts, salmonid alphavirus is referred to in Commission Implementing Decision (EU) 2021/260 of 11 February 2021, approving national measures designed to limit the impact of certain diseases of aquatic animals in accordance with Article 226(3) of Regulation (EU) 2016/429 of the European Parliament and of the Council and repealing Commission Decision 2010/221/EU.

## 1.1.3. Terms of Reference

In view of the above, the Commission asks EFSA for a scientific opinion as follows:

- 1) for each of the diseases referred to above, an assessment, taking into account the criteria laid down in Article 7 of the AHL, on the eligibility of the disease to be listed for Union intervention as laid down in Article 5(3) of the AHL;
- 2) for each of the diseases mentioned above:
  - a) an assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9(1) of the AHL;
  - b) a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.

## 1.2. Interpretation of the terms of reference

The interpretation of the ToRs is as in Section 1.2 of the Scientific Opinion on the ad hoc method to be followed for the assessment on listing and categorisation of animal diseases within the AHL framework (EFSA AHAW Panel, 2017a).

The present document reports the results of the assessment on infectious pancreatic necrosis (IPN) according to the criteria of the AHL articles as follows:

- Article 7: IPN profile and impacts;
- Article 5: eligibility of IPN to be listed;
- Article 9: categorisation of IPN according to disease prevention and control rules as in Annex IV. Each category foresees the application of certain disease prevention and control rules to

the respective listed diseases when the disease in question fulfils the criteria laid down in the relevant Section of Annex IV of AHL (Sections 1–5 which correspond to Categories A–E, respectively):

*Category A:* Listed diseases that do not normally occur in the Union and for which immediate eradication measures must be taken as soon as they are detected.

*Category B:* Listed diseases, which must be controlled in all Member States with the goal of eradicating them throughout the Union.

*Category C:* Listed diseases which are of relevance to some Member States and for which measures are needed to prevent them from spreading to parts of the Union that are officially disease-free or that have eradication programmes for the listed disease concerned.

*Category D:* Listed diseases for which measures are needed to prevent them from spreading on account of their entry into the Union or movements between Member States.

*Category E:* Listed diseases for which there is a need for surveillance within the Union;

- Article 8: List of animal species related to IPN.

## 2. Data and methodologies

In order to address the ToRs as provided by the Commission, regarding the listing and categorisation of animal diseases within the framework of AHL, EFSA AHAW Panel has developed an ad hoc methodology for the data collection and the assessment (EFSA AHAW Panel, 2017a). This ad hoc methodology has been used for assessing any animal diseases in a uniform and consistent way and is the one used also for the current Scientific Opinion and constitutes the Protocol of the Assessment.

For the needs of the listing and categorisation of aquatic animal diseases, the following deviations in Sections 2.1.2 and 2.3.1 of the ad hoc methodology (EFSA AHAW Panel, 2017a) were considered necessary for the assessment:

- An EFSA working group (WG) of experts with expertise in aquatic animal diseases was established to support the assessment of the EFSA AHAW panel.
- Section 2.1.2: The fact sheet on the disease profile has been outsourced not only to experts with disease-specific expertise but also to experts with expertise in veterinary epidemiology or in aquatic animal diseases. The fact sheet was reviewed by the EFSA WG of experts and the comments provided were addressed by the contractor.
- Section 2.3.1: In addition to at least 10 AHAW Panel experts as foreseen in the Methodology (EFSA AHAW Panel, 2017a), five experts from the EFSA WG with expertise in aquatic animal diseases participated in the judgement.

The following assessment was performed by the EFSA Panel on Animal Health and Welfare (AHAW) based on the information collected and compiled in form of a fact sheet as in Section 3.1 of the present document. The outcome is the median of the probability ranges provided by the experts, which are accompanied by verbal interpretations only when they fall within the ranges as spelt out in Table 1.

**Table 1:** Approximate probability scale recommended for harmonised use in EFSA (EFSA Scientific Committee, 2018)

Probability term	Subjective probability range
Almost certain	99–100%
Extremely likely	95–99%
Very likely	90–95%
Likely	66–90%
About as likely as not	33–66%
Unlikely	10–33%
Very unlikely	5–10%
Extremely unlikely	1–5%
Almost impossible	0–1%

### 3. Assessment

#### 3.1. Assessment according to article 7 criteria

This section presents the assessment of IPN disease according to the criteria of Article 7 of the AHL and the related parameters in table 2 of the Scientific Opinion on ad-hoc methodology; (EFSA AHAW Panel, 2017a). The assessment is based on the information contained in the factsheet as drafted by the selected contractor (see Section 2.1 of the Scientific Opinion on the ad hoc methodology) and reviewed by the EFSA working group of experts.

##### 3.1.1. Article 7(a) disease profile

IPN is caused by a double-stranded unenveloped RNA virus, the infectious pancreatic necrosis virus (IPNV), which belongs to the genus *Aquabirnavirus* within the family of *Birnaviridae* viruses. It has a worldwide distribution and predominantly infects members of the *Salmonidae* family.

*Aquabirnavirus* strains were first classified based on serological typing into two serogroups (A and B) with nine serotypes within serogroup A and one in serogroup B, using serum neutralisation tests (Hill and Way, 1995). Later on, the isolates were classified into seven genogroups (Blake et al., 2001; Nishizawa et al., 2005). There is a correspondence between the type strain, the serotype and the genotype (Table 2). For instance, the American type strains West Buxton (USA) and Jasper (Canada) correspond to Genotype 1 and Serotypes A1 and A9, respectively (Dopazo, 2020; Tapia et al., 2022).

Although initially isolated from cultured brook trout (*Salvelinus fontinalis*) and considered to induce a disease of great impact in cultured salmonids, IPNV has also been isolated from non-salmonid fish. The International Committee on the Taxonomy of Viruses (ICTV)<sup>3</sup> currently distinguishes three species of *aquabirnaviruses* (Delmas et al., 2019): (i) IPNV which is the type species for *aquabirnaviruses*, (ii) Yellowtail ascites virus (YTAV) which causes diseases in yellowtail fish (*Seriola quinqueradiata*) and (iii) Tellina virus (TV) which infects *Tellinus telius* molluscs. Other closely related viruses, such as the marine birnavirus AY-98, have not yet been approved as a species in the genus *aquabirnavirus* (Munang'andu et al., 2016; Mutoloki et al., 2016; Eriksson-Kallio, 2022). The working definition of IPNV used in this review corresponds to the current broad species ICTV definition and includes all IPNV isolates except for YTAV and TV (Table 2).

IPNV gains entry through the susceptible host's gills, gut and certain areas of the skin. Within a few days, the virus is detected in several tissues; given that it has been detected in circulating leucocytes, it is believed that the presence of the virus in the blood during the viraemia phase is the reason behind the rapid distribution of IPNV through most of the fish tissues. Predilection sites for the primary replication of the virus in internal organs, including the head kidney, where maximum replication is reached, and, during acute infection, also the intestine and pancreas. Pancreatic, pylorus, pyloric caeca and anterior intestine tissues undergo severe necrosis. Degenerative changes also occur in the kidney, liver and spleen. Most fish that survive the disease can become subclinical carriers. These persistently infected fish are a source of horizontal transmission, shedding the virus in their faeces, particularly under stressful conditions like spawning. In persistently infected fish, IPNV is present in macrophages within the haematopoietic tissue of the kidney (Munang'andu et al., 2016; Dhar et al., 2017; Dopazo, 2020). The ability of IPNV to persist in asymptomatic reservoir hosts as a result of an incomplete immunity development, as well as the continuous shedding of the virus from some proportion of infected animals, presents a mechanism for long-term virus maintenance. Moreover, IPNV may survive and be transmitted via a range of vector species (Munro and Midtlyng, 2011).

<sup>3</sup> <https://ictv.global/taxonomy>.

**Table 2:** Genera of *aquabirnaviruses*: different types of taxonomy and the correspondence between the strain type, the serotype and the genotype

Serological typing			Genotyping isolates	<i>Aquabirnaviruses</i> species
(Hill and Way, 1995; Riji John and Richards, 1999; Dixon et al., 2008; Nobiron et al., 2008)			(Blake et al., 2001; Nishizawa et al., 2005; Dopazo, 2020)	Delmas et al. (2019) (ICTV)
Serogroup	Serotypes	Strain types	Genogroups	Species
A	A <sub>1</sub>	WB (West Buxton), VR-299	1	Infectious pancreatic necrosis virus (IPNV)
	A <sub>2</sub>	Sp (Spjarup) <sup>(a)</sup>	5	
	A <sub>3</sub>	Ab (Abild) <sup>(b)</sup>	2	
	A <sub>4</sub>	He (Hecht); 94/01	6	
	A <sub>5</sub>	Te (TV-2)	3	
	A <sub>6</sub>	Canada 1	3	
	A <sub>7</sub>	Canada 2	4	
	A <sub>8</sub>	Canada 3	4	
	A <sub>9</sub>	Ja (Jasper)	1	
Not assigned	Not assigned	YTAV	7	Yellowtail ascites virus (YTAV) – (marine birnaviruses; MABV)
B	B1	TV-1	Not assigned	Tellina virus (TV)
C	C1	Blotched snakehead virus (BSNV)	Not assigned	Not assigned
D	D1	Not assigned	Not assigned	Not assigned
	D2	Not assigned	Not assigned	

The grey shade is for the serotypes and Strain type that belong to Infectious Pancreatic necrosis virus and are those of our concern.

(a): Type strain Sp: from farmed rainbow trout near village Spjarup in Denmark.

(b): Type strain Ab: from farmed rainbow trout near village Abild in Denmark.

### 3.1.1.1. Article 7(a)(i) Animal species concerned by the disease

#### *Susceptible animal species*

##### Parameter 1 – Naturally susceptible wildlife species (or family/orders)

The species most susceptible to IPN are salmonids, mainly rainbow trout (*Oncorhynchus mykiss*), brook trout (*Salvelinus fontinalis*), brown trout (*Salmo trutta*), Atlantic salmon (*Salmo salar*) (Smail et al., 2006) and several Pacific salmon species (*Oncorhynchus* spp.), in which the virus produces the most frequent and characteristic clinical signs (Smail and Munro, 2012). Susceptibility is reported to decrease with age in salmonids (Centre for Environment Fisheries and Aquaculture Science, 2021). Fish species naturally susceptible to IPNV are listed in Table 3 (Munang'andu et al., 2016; Fisheries and Ocean Canada, 2017; Rimsta, 2019; Duan et al., 2021; Tapia et al., 2022).

##### Parameter 2 – Naturally susceptible domestic/farmed species (or family/orders)

The susceptible species (wild and farmed) through natural infection are described in Table 3.

**Table 3:** IPN-susceptible species (wild and farmed) through natural infection

Fish species ( <i>Scientific name</i> )	Serotype	Genogroup	Wild/ farmed	Reference
<b>Amago salmon</b> ( <i>Oncorhynchus rhodurus</i> )	A <sub>1</sub>	1	Farmed	Jung et al. (1999), Zhang and Suzuki (2003)
<b>Arctic charr</b> ( <i>Salvelinus alpinus</i> )	A <sub>8</sub>	4	Farmed	Blake et al. (2001)
<b>Atlantic halibut</b> ( <i>Hippoglossus hippoglossus</i> )	A <sub>2</sub>	Not available	Farmed	Biering et al. (1994), Rodger and Frerichs (1997)



Fish species ( <i>Scientific name</i> )	Serotype	Genogroup	Wild/farmed	Reference
<b>Atlantic menhaden</b> ( <i>Brevoortia tyrannus</i> )	Serotype 1	Not available	Wild	Stephens et al. (1980), Nicholson and Caswell (1982), Stephens et al. (1980)
<b>Atlantic salmon</b> ( <i>Salmo salar</i> )	A <sub>6</sub> A <sub>2</sub> A <sub>1</sub>	3 5 1 6	Wild and farmed	Blake et al. (2001), Shivappa et al. (2004), Cutrín et al. (2004), Persson et al. (2023)
<b>Brook trout</b> ( <i>Salvelinus fontinalis</i> )	A <sub>1</sub>	1, 6	Farmed	Blake et al. (2001)
<b>Brown/sea trout</b> ( <i>Salmo trutta</i> )	A <sub>2</sub>	5, 6	Farmed	Rexhepi et al. (2011), Ulrich et al. (2018)
<b>Chinook salmon</b> ( <i>Oncorhynchus tshawytscha</i> )	A <sub>2</sub>	5	Wild and farmed	Davies et al. (2010)
<b>Chum salmon</b> ( <i>Oncorhynchus keta</i> )	A <sub>1</sub> A <sub>3</sub>	1 2	Farmed	Jeon et al. (2011)
<b>Coho salmon</b> ( <i>Oncorhynchus kisutch</i> )	A <sub>1</sub>	1	Farmed	Lopez-Lastra et al. (1994), Eissler et al. (2011)
<b>Common dab</b> ( <i>Limanda limanda</i> )	A <sub>5</sub>	Not available	Farmed	Diamant et al. (1988), Wallace et al. (2008)
<b>Cutthroat trout</b> ( <i>Oncorhynchus clarkii</i> )	A <sub>1</sub>	1	Farmed	Blake et al. (2001)
<b>European eel</b> ( <i>Anguilla anguilla</i> )	A <sub>3</sub>	Not available	Farmed	Hudson et al. (1981)
<b>Hake</b> ( <i>Merluccius merluccius</i> )	Serogroup A	99.55% degree of nucleotide similarity to the farmed salmon IPNV isolate from the same geographic location (genogroup 5)	Wild	Wallace et al. (2005)
<b>Japanese eel</b> ( <i>Anguilla japonica</i> )	A <sub>3</sub>	2	Farmed	Kim and Oh (2014)
<b>Lake trout</b> ( <i>Salvelinus namaycush</i> )	A <sub>2</sub>	5	Farmed	Maj-Paluch et al. (2020)
<b>Lemon sole</b> ( <i>Microstomus kitt</i> )	Serogroup A	Not available	Wild	Wallace et al. (2008)
<b>Pike</b> ( <i>Esox lucius</i> )	A <sub>4</sub>	6	Farmed	Ahne (1978), Hill and Way (1995)
<b>Pink salmon</b> ( <i>Oncorhynchus gorbuscha</i> )	Serogroup A	Not available	Wild and farmed	Hill and Way (1995)
<b>Plaice</b> ( <i>Pleuronectes platessa</i> )	Serogroup A	Not available	Wild	Wallace et al. (2008)
<b>Rainbow trout</b> ( <i>Oncorhynchus mykiss</i> )	A <sub>1</sub> , A <sub>3</sub> , A <sub>4</sub> , A <sub>7</sub> , A <sub>9</sub>	1,2, 4,5	Farmed	Bebak and McAllister (2009), Blake et al. (2001)
<b>Snakehead fish</b> ( <i>Channa striata</i> )	A <sub>2</sub>	Not available	Farmed	Wattanavijarn et al. (1988)
<b>Striped bass</b> ( <i>Morone saxatilis</i> )	Closely related antigenically to WB strain	Not available	Farmed	Schutz et al. (1984)
<b>Turbot</b> ( <i>Scophthalmus maximus</i> )	A <sub>3</sub>	2	Farmed	Mortensen et al. (1993), Castric et al. (1987), Duan et al. (2021)

Fish species ( <i>Scientific name</i> )	Serotype	Genogroup	Wild/ farmed	Reference
Whitefish ( <i>Coregonus lavaretus</i> )	A <sub>3</sub>	2	Farmed	Eriksson-Kallio et al. (2016)
Atlantic cod ( <i>Gadus morhua</i> )	A2	5	Farmed	Lorenzen et al. (1995)

#### Parameter 3 – Experimentally susceptible wildlife species (or family/orders)

Fish species that were found to be experimentally susceptible to IPNV, and that are not already mentioned in the list of naturally susceptible fish species in the table above (Table 3) are reported in Table 4.

#### Parameter 4 – Experimentally susceptible domestic/farmed species (or family/orders)

The domestic (farmed) species susceptible to IPNV experimentally are described in Table 4.

**Table 4:** Wild and farmed aquatic animals experimentally susceptible to IPNV

Aquatic animal species	Wild/ farmed	Experiment setting	Reference
Atlantic cod ( <i>Gadus morhua</i> )	Not available	Infected by intraperitoneal injection, cohabitation and immersion	Urquhart et al. (2009)
Freshwater crayfish ( <i>Astacus astacus</i> )	Farmed	Injection with Sp* strain	Halder and Ahne (1988)
Goldsinny wrasse, ( <i>Ctenolabrus rupestris</i> )	Farmed	Injection with Sp* strain	Gibson et al. (1998)
Spotted wolffish ( <i>Anarhichas minor</i> )	Wild	Bath-challenge in oxygenated seawater containing isolates H-IPNV/GW98 and S-IPNV/SH96	Sommer et al. (2004)
Zebrafish ( <i>Danio rerio</i> )	Not available	Injection with Sp* strain	Rud et al. (2020)

\*: Sp (Spjarup) see also Table 2.

#### Reservoir animal species

#### Parameter 5 – Wild reservoir species (or family/orders)

Both freshwater and marine animals and fish can be carriers of IPNV, particularly around the vicinity of infected farms, where survivors of IPN outbreaks can become lifelong carriers, thus serving as reservoirs of the virus (FHL and VESO, 2003; Ruane et al., 2007). In a survey of 30,000 marine fish on the coast of Scotland, IPNV was isolated according to the method of Munro et al. (2004) and confirmed by enzyme-linked immunosorbent assay (ELISA) in nine species of fish: common dab (*Limanda limanda*), plaice (*Pleuronectes platessa*), lemon sole (*Microstomus kitt*), flounder (*Platichthys flesus*), long rough dab (*Hippoglossoides platessoides*), saithe (*Pollachius virens*), grey gurnard (*Eutrigla gurnardus*), hake (*Merluccius merluccius*) and Whiting (*Merlangius merlangus*). This suggests these species may act as reservoirs of the pathogen (Wallace et al., 2008). However, there is also evidence that IPNV-infected wild salmonid species naturally infected by IPNV do not sustain the infection and are not self-sustaining as a natural infection (i.e. not enzootic) (Munro et al., 1976; FHL and VESO, 2003). IPNV has also been isolated from other asymptomatic species such as grayling (*Thymallus thymallus*) (Ahne, 1980; Dorson, 1982; Hill and Way, 1995), huchen (*Hucho hucho*) (Ahne, 1980; Hill and Way, 1995). In addition, brook trout (*Salvelinus fontinalis*) have been shown to be asymptomatic chronic carriers of IPNV in experimental trials (Bootland et al., 1991).

Birnaviruses have also been isolated from naturally occurring infections in molluscs (limpets, periwinkles, mussels, oysters, scallops, tellina, venerid clams) crustaceans (European crayfish, *Daphnia*, palaemonid shrimps, penaeid prawns, portunid crabs) and rotifers, but it was not clear from the publication whether these comprised IPNV infections (McAllister, 2007). IPNV (WB strain) was shown experimentally to be able to bioaccumulate in blue mussel (*Mytilus edulis*) and be transmitted to naive Atlantic salmon (*Salmo salar*) smolts (Molloy et al., 2013). Another experiment found that swan mussel (*Anodonta cygnea*) was resistant to IPNV, but able to accumulate and maintain substantial levels of

the virus for 35 days (Rud et al., 2020). The following is a list of fish families where aquatic birnaviruses were isolated as a naturally occurring infection (McAllister, 2007), but it was not clarified in the publication if the virus described was IPNV: *Acipenseridae*, *Amiidae*, *Anguillidae*, *Atherinidae*, *Bothidae*, *Carangidae*, *Catostomidae*, *Centrarchidae*, *Cichlidae*, *Channidae*, *Clupeidae*, *Cobitidae*, *Coregonidae*, *Cottidae*, *Cyprinidae*, *Cyprinodontidae*, *Embiotocidae*, *Esocidae*, *Gadidae*, *Gasterosteidae*, *Gobiidae*, *Hiodontidae*, *Ictaluridae*, *Lepisosteidae*, *Moronidae*, *Paralichthyidae*, *Percichthyidae*, *Percidae*, *Petromyzontidae*, *Pleuronectidae*, *Poeciliidae*, *Polyodontidae*, *Salmonidae*, *Sciaenidae*, *Soleidae*, *Thymallidae*, *Triglidae*, *Umbridae*.

#### Parameter 6 – Domestic/farmed reservoir species (or family/orders)

Farmed fish are an important reservoir of IPNV in aquatic environments, where the virus can be shed from farm waters into surroundings. Similarly, IPNV has also been isolated from other asymptomatic farmed aquatic species such as tilapia (*Tilapia mossambica*) (Mulei et al., 2018), Atlantic cod (*Gadus morhua*) (Duan et al., 2021), common seabream (*Pagrus pagrus*) (Lopez-Jimena et al., 2010). Many farmed fish species are the same as those listed in Parameter 5 since these fishes were found in wildlife and then collected and raised for aquacultural purposes: Barb (*Luciobarbus graellsii*) (Ortega, 1993), goldfish (*Carassius auratus*), discus fish (*Symphysodon*), bream (*Abramis brama*) (Adair and Ferguson, 1981), brook trout (*Salvelinus fontinalis*) (Bootland et al., 1991), Atlantic salmon (*Salmo salar*) (Bowden et al., 2002; FHL and VESO, 2003).

#### *Vector animal species*

#### Parameter 7 – Wild vector species (or families/orders)

There is a range of aquatic and terrestrial species that can transmit IPNV from one water source to another. Shellfish and marine crustaceans such as the noble crayfish (*Astacus astacus*) (Halder and Ahne, 1988), the green shore crab (*Carcinus maenas*), the planktonic crustacean *Daphnia magna* and the shrimp *Penaeus japonicus* (Mortensen et al., 1993) have been reported to be potential vectors for IPNV. Also, IPNV has been detected in the copepod sea louse (*Lepeophtheirus salmonis*) although there is no evidence that copepods can serve as vectors of any virus in field studies (Johnson et al., 2004) promoted copepod control (Overstreet et al., 2009). In addition, piscivorous bird species, which prey upon IPNV-infected rainbow trout, were shown to excrete the virus (McAllister and Owens, 1992). Under experimental conditions, trout fry were infected through faeces from heron (*Ardea cinerea*) that consumed infected fish (Peters and Neukirch, 1986). IPNV has also been detected in black-headed gulls (*Chroicocephalus ridibundus*) (Eskildsen and Jorgensen, 1973). Indeed, any bird species that frequent fish farms for opportunistic feeding may be a potential route of IPNV transmission (FHL and VESO, 2003). In terms of mammals, mink may be a possible vector (Sonstegard and McDermott, 1972), as IPNV can be recovered from mink faeces 1 week after experimental inoculation of another animal. Shellfish and marine crustaceans such as the noble crayfish (*Astacus astacus*) (Halder and Ahne, 1988), the green shore crab (*Carcinus maenas*), the planktonic crustacean *Daphnia magna* and the shrimp *Penaeus japonicus* (Mortensen et al., 1993) have been reported to be potential vectors for IPNV. Also, IPNV has been detected in the copepod sea louse (*Lepeophtheirus salmonis*) although there is no evidence that copepods can serve as vectors of any virus in field studies (Johnson et al., 2004) promoted copepod control (Overstreet et al., 2009). In addition, piscivorous bird species, which prey upon IPNV-infected rainbow trout, were shown to excrete the virus (McAllister and Owens, 1992). Under experimental conditions, trout fry were infected through faeces from Heron (*Ardea cinerea*) that consumed infected fish (Peters and Neukirch, 1986). IPNV has also been detected in black-headed gulls (*Chroicocephalus ridibundus*) (Eskildsen and Jorgensen, 1973). Indeed, any bird species that frequent fish farms for opportunistic feeding may be a potential route of IPNV transmission (FHL and VESO, 2003). In terms of mammals, mink may be a possible vector (Sonstegard and McDermott, 1972), as IPNV can be recovered from mink faeces 1 week after experimental inoculation.

#### Parameter 8 – domestic/farmed vector species (or families/orders)

Many domestic/farmed species are the same as those listed in Parameter 7 since these species were found in the wild and then domesticated. For example, noble crayfish (*Astacus astacus*) (Halder and Ahne, 1988), and other marine crustaceans (Mortensen et al., 1993) have been reported to be potential vectors for IPNV. Also, any bird species that frequent fish farms for feeding may be a potential source of IPNV transmission (FHL and VESO, 2003). In addition, chicken (*Gallus domesticus*)



may also be a possible vector (Sonstegard and McDermott, 1972) as IPNV can be recovered from chicken faeces 1 week after experimental inoculation. Among mammals, cows who were experimentally fed a normal grass silage diet where IPN virus-containing fish silage was added were shown to have the virus detected in their faeces for up to 4 days (Smail et al., 1993b).

### 3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations

#### Morbidity

#### Parameter 1 – Prevalence/incidence

IPNV prevalence among farmed fish ranged from less than 1% to 100%. Farm-level prevalence was found to be between 30% and 70%. Among wild fish, IPNV prevalence ranged between less than 1% and 44% (Table 5).

**Table 5:** IPNV (farm-level) prevalence and incidence in wild and farmed fish

Country	Time period	Indicator	Study population	Value	Reference
European countries					
<b>Ireland</b>	2006	Farm-level IPNV prevalence	Farmed Atlantic salmon:		Ruane et al. (2007)
			Marine sites	60%	
			Freshwater sites	30%	
<b>Italy</b>	Not reported	Farm-level IPNV prevalence	Not reported	40%	Panzarin et al. (2018)
<b>Norway</b>	1991	Farm-level IPN-mortality incidence rate	Farmed seawater Atlantic salmon (post-smolt)	39.5% (during the time from sea transfer)	Jarp et al. (1995)
<b>Norway</b>	2011–2021	Farm-level clinical IPN incidence	Farmed salmonids	Range: 19–154 sites/year	Sommerset et al. (2022)
<b>Spain</b>	2010–2011	IPNV prevalence	Wild marine fish:		Moreno et al. (2014)
			Oceanographic	25.7%	
			River mouth	44.4%	
The United Kingdom at the time of the disease occurrence was an EU MS					
<b>United Kingdom (Scotland)</b>	1990–2002	Clinical IPN prevalence	Farmed Atlantic salmon (marine sites)	Range: 0.6–12.5%	Bruno (2004)
<b>United Kingdom (Scotland)</b>	1990–2002	IPNV prevalence	Farmed Atlantic salmon (broodstock sites)	Range: 0.69–23.08%	Munro et al. (2010)
<b>United Kingdom (Scotland)</b>	1996–2001	IPNV prevalence	Farmed Atlantic salmon:		Murray et al. (2003)
			Saltwater	49.6%	
			Freshwater	10.6%	
<b>United Kingdom (Scotland)</b>	2002–2004	IPNV prevalence	Wild marine fish:		Wallace et al. (2008)
			All	0.2%	
			Flat fish	0.3%	
			Round fish	0.1%	
Non-European countries					
<b>Chile</b>	2010–2013	Farm-level IPN-mortality prevalence	Farmed Atlantic salmon (marine sites)	Range: 28.8–66.6%	Escobar-Dodero et al. (2019)
<b>Chile</b>	2012–2013	IPNV prevalence	Farmed Atlantic salmon and rainbow trout (freshwater and marine sites)	100%	Tapia et al. (2015)

Country	Time period	Indicator	Study population	Value	Reference
<b>Mexico</b>	2000–2012	IPNV prevalence	Farmed trout (freshwater sites)	Range: 3–53%	Ortega et al. (2016)
<b>Turkey</b>	2007–2008	IPNV prevalence	Farmed rainbow trout (marine cage culture)	Range: 0–100%	Ogut and Altuntas (2012)
<b>Turkey</b>	2014–2014	Farm-level IPNV prevalence	Farmed rainbow trout (freshwater sites)	71%	Büyükekiz et al. (2018)

#### Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)

No information was found in the publications. However, comparing the number of sites where IPNV has been isolated to the number of clinical outbreaks reported in Ireland between 1993 and 2007 (Ruane et al., 2007), we can conclude that an IPNV infection does not automatically lead to a clinical outbreak; for instance, in 2006, IPNV was isolated in 14 Atlantic salmon sites, whereas only six clinical outbreaks were reported that year. Susceptibility generally decreases with age, with high mortality observed in fish fry and fingerlings between 1 and 4 months of age. Atlantic salmon smolts transferred to seawater are also at risk of death, with rates increasing in infected animals 7–12 weeks after their transfer. This is indeed considered a stressful time for fish undergoing physiological adaptation to seawater, which suppresses immunity, thus increasing susceptibility to infection (Urquhart et al., 2008; Canadian Food Inspection Agency, 2020). The implementation of the quantitative trait loci (QTL) breeding in aquacultures reduces the case-morbidity rates since QTL fish are resistant to IPN (FHL and VESO, 2003; Tapia et al., 2022). In addition, underreporting should be considered since IPN is not a notifiable disease.

#### Mortality

##### Parameter 3 – Case-fatality rate

Mortality rates in the freshwater stage vary considerably from very low to almost 100%, while disease outbreaks in seawater typically result in 10–20% cumulative mortality and can reach 70% in individual sea cages. In the context of experimental studies carried out among salmonids, mortality was found to range from 0% to 100% (Rimsta, 2019). This variation in mortality has been ascribed to factors related to the host species such as age or genetic resistance of fish, environmental stressors and virus characteristics (Frantsi and Savan, 1971; Evensen and Santi, 2008). Crude mortality is often used as a response variable, but no studies have focused on the IPN-specific part of this figure (FHL and VESO, 2003). Examples of mortality rates observed during field outbreaks are described in Table 6.

**Table 6:** Examples of mortality rates observed during field outbreaks

Country	Time period	Indicator	Study population	Value	Reference
European countries					
<b>Finland (inland)</b>	2012–2014	Mortality rate	Farmed rainbow trout and whitefish (freshwater sites)	Range: < 1–40%	Eriksson-Kallio et al. (2016)
<b>Greece</b>	2000	Mortality rate	Rainbow trout (fry and fingerling)	30–55%	Varvarigos and Way (2002)
<b>Norway</b>	1991	Mortality rate adjusted for significant risk factors	Farmed Atlantic salmon (seawater post-smolt)	17.8%	Jarp et al. (1995)
<b>Norway</b>	2009–2012	Mortality rate	Farmed Atlantic salmon and rainbow trout (smolt)	Range: 3.9–28.4% (mean: 14%)	Bang Jensen and Kristoffersen (2015)

Country	Time period	Indicator	Study population	Value	Reference
Norway	2019	Mortality rate	Farmed Atlantic salmon (post-smolt stage; QTL carrying fish)	10%	Hillestad et al. (2021)
UK at the time of the disease occurrence was an EU MS					
United Kingdom (Scotland)	1990–2002	Mortality rate (daily)	Farmed Atlantic salmon (marine sites)	Range: 0.03–0.5%/day	Bruno (2004)
United Kingdom (Scotland)	1999	Mortality rate	Farmed Atlantic salmon (post-smolt)	11%	Smail et al. (2006)
United Kingdom (Scotland)	2002	Mortality rate	Farmed Atlantic salmon (freshwater fry)	Range: 0–60%	McLoughlin and Weigall (2002)
Non-European countries					
Chile	2010–2013	Mortality rate	Farmed Atlantic salmon (marine sites)	Range: 0.01–13%	Escobar-Dodero et al. (2019)
China	2016	Mortality rate	Farmed rainbow trout	~ 100%	Zhu et al. (2017)
Iran	2009	Mortality rate	Farmed rainbow trout (fry)	90%	Ghasemi et al. (2011)
Iran	2015–2017	Mortality rate	Farmed rainbow trout	Range: 30–60%	Ahmadivand et al. (2020)
Turkey	2002	Mortality rate	Rainbow trout (fry)	50%	Candan (2002)

### 3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease

#### Parameter 1 – Report of zoonotic human cases (anywhere)

IPN is not a zoonotic disease. There is no evidence in the literature that IPNV infects humans.

### 3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance

#### Parameter 1 – Resistant strain to any treatment; even at laboratory level

Not applicable. No effective treatment for IPN is currently available.

### 3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the environment

#### Animal population

#### Parameter 1 – Duration of the infectious period in animals

Fish become infectious and begin shedding IPNV after about 2 days of latency and continue shedding the virus for about the next 10 days (McAllister, 2007). Urquhart et al. (2008) observed that viral shedding from acutely infected fish occurs over a period of 12 days and that peak viral shedding occurs just prior to, or at the time of, death following challenge by intraperitoneal infection. It is important to take into account the fact that fish surviving IPNV infection can become asymptomatic carriers of the virus for long periods of time, possibly for life (Hill, 1982).

#### Parameter 2 – Presence and duration of the latent infection period

Fish become infectious and begin shedding the virus after about 2 days of latency (McAllister, 2007). Experimental infection trials using fingerling trout indicate that there is a latent period of about 2 days after infection before infected fish begin to shed detectable quantities of IPNV into the water (Smith et al., 2000).

#### Parameter 3 – Presence and duration of the pathogen in healthy carriers

Survivors of an IPN epidemic can become persistent carriers and intermittently shed the virus in excretory and reproductive products, typically during periods of stress (Wolf and Quimby, 1969;

Dorson, 1982; Hill, 1982; Melby et al., 1991). This results in the shedding of more viruses, which increases the risk of infecting virus-free fish stocks and of the recurrence of IPN in the carrier population (FHL and VESO, 2003). In Atlantic salmon, the carrier state is very frequent in fish that survive an IPN outbreak, and they are anticipated to become lifelong carriers (Melby et al., 1991). Rainbow trout adults, whether experimentally (Ahne and Thomsen, 1986) or naturally infected (Yamamoto, 1974), have an unpredictable persistence of the IPNV carrier state, ranging from 10 months to over 2 years (Bootland et al., 1991). The natural carrier state occurs more frequently and persists for a longer time in brook trout than in rainbow trout (Yamamoto, 1974; Sadasiv, 1995; Rodriguez Saint-Jean et al., 2003). Furthermore, persistent IPNV strains can also be recovered from QTL-resistant fish (Benkaroun et al., 2021).

### Environment

#### Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil, water, air) from the environment (scenarios: high and low temperatures)

Due to the demonstrated stability of *aquabirnaviruses* in a wide range of temperatures, pH and salinity, IPNV can survive for long periods of time in a variety of environmental scenarios and different types of reservoirs (Dopazo, 2020; Woo et al., 2020).

Previous studies have shown that IPNV is stable in seawater for at least 11 days, but gradually loses infectivity in media of lower salinity (Moewus-Kobb, 1965). Tu et al. (1975) demonstrated that IPNV suspended in a fresh stream or well water, retained almost all its infectivity for about 10 days at 4°C and 5 days at 15°C. Barja et al. (1983) reported that IPNV remained infective for up to 15–20 days in freshwater. Toranzo and Hetrick (1982) showed inactivation of the virus after 17 days at 15°C and 9 days at 20°C. IPNV appears to be more stable in seawater with reported survival of 20 days and 14–17 days, as reported by Barja et al. (1983), Toranzo and Hetrick (1982) and Ruane et al. (2007). It would be expected that survival of the virus at 4°C in seawater would also follow a similar pattern to survival in fresh water (Oidtmann et al., 2018).

In addition, IPNV has been isolated from sediments during routine surveys around fish farms in Spain, although it was not confirmed whether the isolates were of farmed origin (Rivas et al., 1993). IPNV was also detected in faeces up to 72 h after feeding a contaminated fish silage mixture (with normal grass silage) to cows (Smail et al., 1993b).

### **3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals, and, when relevant, between animals and humans**

#### *Routes of transmission*

#### Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)

Once IPNV has been introduced into a population, horizontal transmission occurs as the virus is disseminated in the surrounding freshwater or seawater via the faeces and urine of infected fish and as fish pass contaminated water through their buccal cavity and over their gills (Mangunwiryono and Agius, 1988; Smith et al., 2000). Moreover, the survivors of an infection usually become carriers of the virus (see Section 3.1.1.4), acting as reservoirs of the virus and spreading it during stress episodes via faeces (Munro and Midtlyng, 2011; Dopazo, 2020). It appears that carrier fish represent the most significant source of horizontal transmission (FHL and VESO, 2003). In addition, a range of vectors and reservoirs may serve as passive mechanical vectors for horizontal transmission of IPNV to fish. For instance, piscivorous birds preying on rainbow trout fry infected with IPNV were shown to excrete the virus in their faeces (McAllister and Owens, 1992; McAllister, 2007).

Vertical transmission of IPNV to progeny has been shown to occur via eggs in brook trout (Bootland et al., 1991) and rainbow trout (Wolf et al., 1963; Ahne, 1983). Dorson and Torchy (1985) used artificially infected rainbow trout sperm to fertilise virus-free eggs and this resulted in clinical disease in the progeny fry. Although the study by Bootland et al. (1991) demonstrated vertical transmission in brook trout, it was noted that transmission is very unpredictable and there is therefore little probability of observing this outside laboratory conditions (Laidler, 2002).

It has never been shown with certainty that vertical transmission can occur for Atlantic salmon (Ahne, 1985; Dorson and Torchy, 1985; Laidler, 2002; FHL and VESO, 2003). However, previous research indicated the presence of IPNV in gonads and gonadal fluids of maturing broodstock, and showed experimentally that a virus could enter the ovum adsorbed to spermatozoa and can survive with the ovum (McLoughlin and Weigall, 2002). Moreover, Scotland's control programmes in freshwater

salmon farms found that the systematic removal of IPNV-positive genital products leads to a decline in the incidence of IPN outbreaks (FHL and VESO, 2003). IPNV has also been detected in eyed eggs and in yolk sac fry (Ahne, 1985). It has never been shown with certainty that vertical transmission can occur for Atlantic salmon (Ahne, 1985; Dorson and Torchy, 1985; Laidler, 2002; FHL and VESO, 2003). However, previous research indicated the presence of IPNV in gonads and gonadal fluids of maturing broodstock, and showed experimentally that virus can enter the ovum adsorbed to spermatozoa and can survive with the ovum (McLoughlin and Weigall, 2002). Moreover, Scotland's control programmes in freshwater salmon farms found that the systematic removal of IPNV-positive genital products leads to a decline in the incidence of IPN outbreaks (FHL and VESO, 2003). IPNV has also been detected in eyed eggs and in yolk sac fry (Ahne, 1985), thereby indicating that eggshells could be involved in the transmission of viruses from one generation to the next and that eggshells may be important in horizontal dispersal in fry that have begun to take in nutrients.

**Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including foodborne)**

Not applicable. IPN is not zoonotic.

*Speed of transmission*

**Parameter 3 – Incidence between animals and, when relevant, between animals and humans**

Data on the incidence of IPN have been described previously (see Section Morbidity, Parameter 1).

**Parameter 4 – Transmission rate (beta) (from  $R_0$  and infectious period) between animals and, when relevant, between animals and humans**

Table 7 below presents the transmission rate found in the publications.

**Table 7:** Transmission rate (beta) and (from  $R_0$  and infectious period) between animals

Country	Time period	Indicator	Study population	Transmission rate (beta)	Reference
United Kingdom (Scotland)	1996–2003	Basic reproduction ratio	Farmed salmon:		Murray (2006)
			Freshwater	1.41	
			Seawater	1.45	
Ireland	1994–2005	Basic reproduction ratio	Farmed salmon:		Ruane et al. (2007)
			Freshwater	2.39	
			Seawater	1.66	
Mexico	2000–2012	Transmission rate	Rainbow trout	1.28	Ortega et al. (2016)
NA (experimental)	NA	Transmission rate	Rainbow trout (fry)	0.013	Smith et al. (2000)

NA: not available.

**3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the union, and, where the disease is not present in the union, the risk of its introduction into the union**

*Presence and distribution*

**Parameter 1 – Map where the disease is present in the EU**

A map was not available from WAHIS. A map presenting the geographical distribution at the country level of IPN outbreaks occurrence in Europe per year is available from the Universidade de Santiago de Compostela.<sup>4</sup> The map in Figure 1 presents the EU countries in Europe where IPN occurred from 2014 to 2021 according to the annual reports of the European Reference Laboratory for Fish and Crustaceans.<sup>5</sup>

<sup>4</sup> <https://www.usc.gal/gl/institutos/acuicultura/difusion/aportacions-cientificas.html>.

<sup>5</sup> <https://www.eurl-fish-crustacean.eu/fish/survey-and-diagnosis>.





water (Rimsta, 2019). The water supply for a hatchery can harbour fish and invertebrates that are carriers of the IPNV. The introduction of free virus via the water supply is thought to occur, although no one has yet isolated IPNV from open or closed water supplies (Maheshkumar et al., 1991; Bebak et al., 1998). Predatory birds can transfer infected fish between raceways and from water supplies outside of a hatchery and IPNV has also been imported on bird faeces (McAllister and Owens, 1992) and bird bills, beaks, feathers and legs (Peters and Neukirch, 1986; Smith et al., 2000).

#### Parameter 4 – Number of animal moving and/or shipment size

This parameter is not relevant for the assessment since IPNV has already been introduced in EU and the disease is endemic.

#### Parameter 5 – Duration of the infectious period in animal and/or commodity

Not applicable because the risk of introduction to the EU is not relevant as the disease is endemic. Information on the infectious period at the individual level is provided in Section 3.1.5.

#### Parameter 6 – List of control measures at the border (testing, quarantine, etc.)

This parameter is not relevant for the assessment since IPNV has already been introduced in EU and the disease is endemic.

IPN is not a listed disease as defined in Regulation (EU) 2016/429. However, Denmark, Finland, Slovenia and Sweden apply specific national control measures designed to limit the impact of the disease since compartments and zones in these areas are regarded as being free of the disease (Commission Implementing Decision (EU) 2022/1188). In this context, in Sweden, there is active surveillance in place for IPNV in imported quarantined eels; 120 glass eels are sampled at arrival, and after 2 months 120 cohabitated rainbow trout are sampled for detection of the virus (SVA National Veterinary Institute, 2020).

#### Parameter 7 – Presence and duration of latent infection and/or carrier status

Not applicable because the risk of introduction to the EU is not relevant as the disease is endemic. Information on the latent period at the individual level is provided in Section 3.1.5.

#### Parameter 8 – Risk of introduction by possible entry routes (considering parameters from 3 to 7)

This parameter is not relevant for the assessment as IPNV has already been introduced in the EU and the disease is endemic.

### **3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools**

#### *Diagnostic tools*

#### Parameter 1 – Existence of diagnostic tools

IPN diagnosis is based on prior disease history of the farm and fish population, clinical signs and a histopathological examination verifying the presence of characteristic lesions. However, clinical signs and pathology cannot be used to distinguish IPN from other viral diseases and the absence of clinical signs does not ensure that fish are free of IPNV. Confirmatory diagnosis involves isolation of the virus in cell culture followed by immunological or molecular confirmation (FHL and VESO, 2003; Dhar et al., 2017).

Virus isolation by cell culture propagation remains the reference standard for diagnosing IPNV infection in salmonid fish. A former WOAHA manual (no longer available) recommended teleost cell lines include BF-2, CHSE-214 or RTG-2. Tissues used in the inoculation of cells include the kidney, spleen and heart, brain or liver. Ovarian fluids from brood fish at the spawning time may also be used (Eriksson-Kallio, 2022).

The antibody-binding methods used for IPNV diagnosis include neutralisation assays, ELISA, immunofluorescence assays (FAT/IFAT), immunohistochemistry (IHC), co-agglutination tests, immunoblots and flow cytometry. Rodriguez Saint-Jean et al. (2001) demonstrated that flow cytometry might be considered the most reliable antibody-binding method to diagnose IPNV, followed by IFAT (Eriksson-Kallio, 2022).

Reverse transcriptase polymerase chain reaction (RT-PCR) for detecting IPNV nucleic acids has been in use since the mid-1990s. RT-PCR is considered an accurate, rapid and sensitive method used for routine diagnostic confirmation of IPNV (Rodriguez Saint-Jean et al., 2001; Chong, 2022).

Sanger sequencing, considered the reference standard of sequencing technology, is a method to determine nucleotide sequences in DNA based on gel electrophoresis (Sanger et al., 1977). Partial sequence data from the VP2 gene sequence are commonly used for the determination of the IPNV genogroup. The obtained sequences can also be used for phylogenetic analysis (Eriksson-Kallio, 2022).

#### *Control tools*

#### Parameter 2 – Existence of control tools

Although in most EU countries there are no official control measures against IPN in place, the disease can be prevented through a combination of intensive monitoring, biosecurity, targeted vaccines and resistant broodstock (Dhar et al., 2017). Some EU countries apply specific national measures to limit the impact of the disease since these areas are regarded as being partly free of the disease (Commission Implementing Decision (EU) 2022/1188). For example, in Sweden, in order to maintain their free status, both passive and active surveillance activities are in place based on the risk of IPNV introduction in the farms. In addition, active surveillance is implemented in imported quarantined fish (eels) and whenever potential invasive alien species (like the marble crayfish) are discovered (SVA National Veterinary Institute, 2020). Denmark has since 1971 had a national surveillance programme for IPNV in place. In 2019, 26 freshwater fish farms were registered as being IPN-free. Most of these farms are situated along small rivers, where the water source is mainly well water or borehole water. The majority of these IPN-free farms have broodstock and dispatch eggs, fry and fingerlings to Danish trout farms or export them (Danish Veterinary and Food Administration, 2022).

### **3.1.2. Article 7(b) The impact of the disease**

#### **3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture production and other parts of the economy**

##### *The level of presence of the disease in the Union*

#### Parameter 1 – Number of MSs where the disease is present

IPNV and/or aquatic birnaviruses have been reported in 19 European Union Ms: Austria, Croatia, Czechia, Denmark, Finland (Eriksson-Kallio, 2022), France (Castric et al., 1987), Germany, Greece, Ireland (Ruane et al., 2007), Italy, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden (SVA National Veterinary Institute, 2020) and the UK<sup>6</sup> (Bucke et al., 1979; Ulrich et al., 2018). IPN has been also reported in Norway<sup>7</sup> (Somerset et al., 2022) and Switzerland<sup>4</sup> (Bucke et al., 1979).

IPNV has not been notifiable to WOAHA since 2005; thus, reporting is down to the individual MS and is reliant on the effectiveness of surveillance in each country, so knowledge gaps may exist. The Universidade de Santiago de Compostela<sup>8</sup> has mapped IPNV across Europe, which was also used to supplement the above list. More information can be found here: <https://www.usc.gal/es/institutos/acuicultura/difusion/aportacions-cientificas.html>.

##### *The loss of production due to the disease*

#### Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation (milk, growth, semen, meat, etc.)

IPN is economically important due to its lethality for salmonid fry in freshwater production and in post-smolts after transfer to seawater (Dhar et al., 2017).

In Norway, during the period 1994–2000, 40–70% of all seawater sites experienced IPN outbreaks with the average mortality ranging between 10% and 20% (FHL and VESO, 2003). From 1991 to 2002, IPN had an impact on salmon post-smolt survival in Norwegian studies of 6.4–12.0% (Munro and Midtlyng, 2011). A study from Norway on cumulative mortality in the first 6 months after sea transfer showed that mortality in salmonid cohorts with IPN increased to approximately 7.2% as compared with a 'baseline' cohort with a mortality of 3.4% (Bang Jensen and Kristoffersen, 2015; Dhar et al., 2017).

<sup>6</sup> Not EU MS since 31 January 2020, but there is important considerations in the region for IPN.

<sup>7</sup> Not EU MS but there is important considerations in the region for IPN.

<sup>8</sup> <https://www.usc.gal/es/institutos/acuicultura/difusion/aportacions-cientificas.html>.



A survey conducted in 2001 in Scotland showed an average loss due to IPN of 20–30% in salmon post-smolts (Ruane et al., 2007).

In Ireland, in total 910,000 fish died because of IPNV and a further 750,000 were culled during the 2006 IPN outbreak in salmon rearing units (Ruane et al., 2007).

The effect of IPN on salmon production is particularly serious as it can also cause the death of smolts, shortly after they are put to sea. As these smolts are 0.5–2 years old when they are put to sea, they represent a considerable investment, and their loss is economically serious. IPN may also cause losses to salmon production by suppressing of appetite and associated reduced growth rates (Damsgård et al., 1998; Murray et al., 2004).

Moreover, Roberts and Pearson (2005) reported that IPN-recovered freshwater Atlantic salmon frequently developed a greatly distended intestine associated with the accumulation of undigested food. In seawater, after the initial, often significant (50% or more) losses, there were many fish that failed to grow and became chronically emaciated and prone to sea louse infection.

### 3.1.2.2. Article 7(b)(ii) The impact of the disease on human health

IPN is not a zoonotic disease. There is no evidence in the literature that IPNV infects humans.

### 3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare

#### Parameter 1 – Severity of clinical signs at the case level and related level and duration of impairment

IPNV infection varies from inapparent or subclinical, in which losses are limited, to acute outbreaks, in which mortality affects nearly the entire population in the affected fish farm. The severity and cumulative mortalities of IPN infection in salmonids depend on the combination of several factors related to the host, the virus and the environment (Dorson and Touchy, 1981; Rodriguez Saint-Jean et al., 2003). Clinical signs of IPN are unspecific but can include hyperpigmentation, unilateral exophthalmia, coelomic distention, the presence of a mucoid pseudo-cast extruding from the vent and haemorrhages at the base of and in the fins as well as on the body surface. In addition, behavioural changes include anorexia and an agonal corkscrew swimming motion interspersed with ataxia (Wolf, 1988). Marked pathological changes can accompany IPNV infection, such as severe necrosis of pancreatic tissue characterised by condensation of chromatin (pyknosis). Mortality due to IPN is higher in young fish at ages of less than 6 months and rare in older fish. Under experimental conditions, fish die between 3 and 20 days after infection. As mentioned above, survivors of exposure to IPNV may become virus carriers for an extended period (McAllister, 1983; Wolf, 1988; Rodriguez Saint-Jean et al., 2003; McAllister, 2007). However, Damsgård et al. (1998) reported that an IPNV carrier condition in Atlantic salmon did not affect appetite and weight gain when compared with the non-carriers.

### 3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment

#### *Biodiversity*

#### Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list

None of the naturally IPN-susceptible wildlife species is included in CITES or IUCN lists of endangered species. However, the European eel (*Anguilla anguilla*), one of the experimentally susceptible wildlife species (see the Section on Susceptible animal species) is currently present in the two lists.

#### Parameter 2 – Mortality in wild species

Despite the widespread occurrence of IPNV in salmonid farms from Scotland and Norway, no significant effect on wild fish has been observed in those countries. No histopathological signs of IPN were found in wild fish sampled from Irish rivers where hatchery outbreaks had been reported. These findings seem to indicate that IPN is not self-sustaining as a natural infection in wild fish (FHL and VESO, 2003; Ruane et al., 2007). A survey conducted on wild fish in the Scottish Loch Awe has shown a low prevalence of IPNV infection, restricted around a rainbow trout farm where infected stocks had been found previously. No signs of clinical disease were observed in infected wild fish (Munro et al., 1976). However, it is noteworthy that mortality in the youngest fish (fry/parr<sup>9</sup>) may be difficult to observe due to rapid decomposition of corpses; therefore, wild losses are probably underestimated as not directly observed.

<sup>9</sup> When the fry grows to 2 in. long, it is called a parr or fingerling.

## Environment

### Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife

As discussed previously (see the Section on 'Persistence of the disease in an animal population or the environment') fish surviving IPNV infection often remain carriers for long periods and the virus may also survive in the environment such as in the water.

### **3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use in bioterrorism**

#### Parameter 1 – Listed in WOA/CFSPH classification of pathogens

IPN is not listed in CFSPH<sup>10</sup> and is not a WOA-listed disease.<sup>11</sup>

#### Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group

IPN is not listed in the Encyclopaedia of Bioterrorism Defence of Australia Group.<sup>12</sup>

#### Parameter 3 – Included in any other list of potential bio- agro-terrorism agents

IPN is not listed as a potential bio-agro-terrorism agent.

### **3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following disease prevention and control measures**

#### **3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities**

##### *Availability*

#### Parameter 1 – Officially/internationally recognised diagnostic tool, WOA certified

As IPN is not listed by WOA, the manual on diagnostic tools is no longer available. IPN is no longer included in the WOA manual. Due to its widespread, often endemic occurrence in the salmonid culturing regions of the world, WOA has delisted the disease and it is no longer a listed and notifiable disease.

##### *Effectiveness*

#### Parameter 2 – Se and Sp of diagnostic test

In Canada, the performance of RT-qPCR and the virus isolation test has been validated to assess their fitness as diagnostic tools for the detection of IPNV (Fisheries and Ocean Canada, 2017). The authors report high accuracy estimates of 97% for diagnostic sensitivity (Se) and 98% for diagnostic specificity (Sp) obtained for both tests when samples were from naïve and diseased populations. The estimates generated for the RT-qPCR test using samples from apparently healthy populations remained high at 83–91% for Se and 86–92% for Sp. Poor accuracy was observed for the virus isolation test with samples from the same population (i.e. 22–27% for Se and 87–90% for Sp). The results indicated that the cell culture test is not a suitable tool for the detection of IPNV in apparently healthy populations given the high probability of false-negative results.

Rodriguez Saint-Jean et al. (2001) comparatively evaluated six diagnostic methods for IPNV detection using the seroneutralisation as the reference assay: indirect immunofluorescence, flow cytometry, immunoperoxidase, immunodot blot, immune *Staphylococcus* protein A and RT-PCR. Positive reactions were obtained in 100% of the samples tested by RT-PCR, 90.4% by the flow cytometry, 80.7% by the indirect immunofluorescence assay, 67.5% by the immunoperoxidase, 62.6% by the immunodot blot and only 27.7% by immuno-*Staphylococcus* protein A test. Therefore, RT-PCR and flow cytometry were the most sensitive methods for the routine detection of IPNV in fish.

There is no one RT-qPCR that can detect all the genotypes of IPNV, and therefore, a combination of methods is used.

<sup>10</sup> <http://www.cfsph.iastate.edu/DiseaseInfo/>.

<sup>11</sup> <http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2016/>.

<sup>12</sup> [http://www.australiagroup.net/en/human\\_animal\\_pathogens.html](http://www.australiagroup.net/en/human_animal_pathogens.html).

### Feasibility

#### Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)

For virus isolation, moribund fish are the best for sampling and must be alive when collected (Rodriguez Saint-Jean et al., 2003). Tissues used in the inoculation of cells include head kidney, spleen and heart, encephalon, or liver. Ovarian fluids from brood fish at spawning time may also be used. For surveillance, organ samples from a maximum of 10 fish may be pooled. In the case of small fish, several pools of 5–10 typical diseased fish should be examined. For larger fish, visceral pools could also be a good choice sampling for delivery to the laboratory, and at least 10–15 selected moribund individuals must be tested in pools of 3–5 fish each (Rodriguez Saint-Jean et al., 2003; Eriksson-Kallio, 2022).

Most immunodiagnostic assays apart from the serum neutralisation test will not detect the carrier status if used directly on fish blood/tissue samples, unless they are inoculated onto cell lines initially (Chong, 2022).

In the context of the active IPNV surveillance implemented in Sweden and Denmark, cell culture is performed in pooled samples from different organs (spleen, kidney, heart/brain) in order to detect or rule out the presence of IPNV. A pool consists of organs from up to ten fish (SVA National Veterinary Institute, 2020).

#### 3.1.4.2. Article 7(d)(ii) Vaccination

##### Availability

#### Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)

A licensed (authorised) inactivated whole-virus vaccine (IWV) (Gomez-Casado et al., 2011; Munang'andu and Evensen, 2015; Chong, 2022) is currently in use in Canada, Chile, Ireland, Norway and the United Kingdom. Successful recombinant VP2 (and VP3) capsid proteins subunit vaccines are used in Canada, Chile, Norway and the USA (for more details, see the table 8 below Chong, 2022). There are currently no licensed (authorised) live IPNV vaccines in use, and DNA vaccines have not shown superior protection over IWV vaccines (Mikalsen et al., 2004; Munang'andu et al., 2012; Dhar et al., 2017; Ma et al., 2019a; Eriksson-Kallio, 2022).

**Table 8:** List of IPNV vaccines extracted from the publication of Chong (2022)

IPNV vaccines		
Vaccine type	Efficacy	Status
Inactivated with formalin or $\beta$ -propiolactone <sup>(1)</sup>	Protection by injection, not by oral or immersion	Experimental. Not practical for use in young fry
Live attenuated <sup>(1)</sup>	Production by passage through cells using serotype not protective, but avirulent IPNV strain from <i>Perca fluviatilis</i> was protective when used as immersion hyperosmotic vaccination	Experimental
Subunit recombinant DNA <sup>(1)</sup>	Based on Sp serotype using the VP2 virus protein synthesised in <i>Escherichia coli</i> . No protection against IPNV Sp and IPNV Buhl. rVP2 vaccine in a multivalent product (furunculosis, cold water vibriosis) protected against IPNV in Atlantic salmon smolts.	Experimental Commercial use in Norway
Inactivated whole virus antigen in multivalent vaccine by Pharmaq AS, Aqua health/Novartis <sup>(2)</sup>	Vaccination of smolts before going to sea. Generally, reduces mortality but can have variable results in field.	Commercial use in Norway
Recombinant VP2 protein IPNV antigen vaccine Intervet Norbio <sup>(2)</sup>	Protective	Commercial use in Norway

IPN vaccines		
Vaccine type	Efficacy	Status
ALPHA-JECT by Pharmaq (IPN and furunculosis) <sup>(2)</sup>	General belief that it is protective, more research needed	Commercial use in Ireland
Oral IPN vaccine by Schering Plough-AquaVac <sup>(2)</sup>	General belief that it is protective, more research needed	Commercial use in Chile
Subunit vaccine AquaVac IPN oral by Merck Animal health <sup>(3)</sup>	VP2 and VP3 capsid proteins	Commercial use in Canada
Norvax Minova-6 by Intervet international <sup>(3)</sup>	VP2 capsid protein	Commercial
Birnagen Forte, Aqua health Ltd. Novartis <sup>(3)</sup>	Inactivated IPNV	Commercial use in Canada
Centrovet, Chile <sup>(3)</sup>	Inactivated IPNV	Commercial use in Chile
Microteck international, British Columbia <sup>(3)</sup>	VP2 protein (Trivalent SRS/IPNV/ <i>Vibrio</i> )	Commercial use in Chile and Canada

(1): Rodriguez Saint-Jean et al. (2003).

(2): Ruane et al. (2007).

(3): Dhar et al. (2014).

#### Parameter 2 – Availability/production capacity (per year)

Information on the availability and the production capacity of the vaccines was not found in the literature.

#### *Effectiveness*

#### Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to disease)

There are a limited number of publications demonstrating the efficacy of the IPNV vaccines (Rimstad, 2014). The majority of commercial IPNV vaccines aim to protect salmonid fish in the post-smolt stage in seawater. However, even if the vaccines were efficient, this would still leave the fish vulnerable to IPNV at a young age prior to vaccination. In Norway, outbreak data indicate that current vaccines against IPNV have limited efficacy under field conditions (i.e. commercial farming of Atlantic salmon) (Rimstad, 2014). Although 85% of all smolts at the national level were vaccinated in 2002, the effect of this high coverage on the IPN situation was not revealed (FHL and VESO, 2003). Vaccination against IPNV has not totally resulted in preventing the impact of IPNV because it is most severe in fry, which are not fully immunocompetent, but applying vaccination to broodstock may reduce the risks of vertical transmission (Chong, 2022).

In a well-controlled field study reported by Erdal et al. (2003), two IPN-vaccinated groups of Atlantic salmon showed 50.6 and 53.2% relative protection during a natural outbreak of IPN 6 weeks after sea transfer. Evaluation of protection from vaccination against IPN in a GCP field trial in Norway (Erdal et al., 2003).

Munang'andu et al. (2012) estimated the hazard risk (HR) ratios for the different IPNV vaccines based on post-challenge mortality data in Atlantic salmon and showed that IWV vaccine was more protective than the other vaccine delivery systems ( $HR_{\text{inactivated}} = 0.108$  vs.  $HR_{\text{other vaccines}} = 1.368-2.211$ ). Inactivated whole-virus vaccines induce strong responses because they retain surface-exposed antigens and the inactivated genomic component.

#### Parameter 4 – Duration of protection

No information was found in the publications.

#### *Feasibility*

#### Parameter 5 – Way of administration

Three major routes of vaccine delivery are used for IPN aquatic vaccination: injection (intraperitoneal and intramuscular), immersion and oral administration. Although different oral and bathing vaccination procedures have been described, IPNV vaccines are usually administered by intraperitoneal injection and aim to protect salmonid fish in the seawater stage (Rimstad, 2014).

However, oral vaccination is the preferred method from a fish farmer's perspective as it is stress-free and can be delivered to juvenile fish just developing immunity, prior to release in seawater (Chen, 2017). Ongoing research includes the improvement of the oral delivery of IPN antigens. The expense and inconvenience of injectable vaccines limit their usefulness in large-scale aquaculture beyond one vaccination cycle, so the use of oral vaccines to boost immune activation is attractive (Dhar et al., 2017).

### 3.1.4.3. Article 7(d)(iii) Medical treatments

No effective treatment for IPN is currently available.

#### *Availability*

##### Parameter 1 – Types of drugs available on the market

As currently there is no treatment available for IPN, Parameter 1 is not applicable for the assessment.

##### Parameter 2 – Availability/production capacity (per year)

As currently there is no treatment available for IPN, Parameter 2 is not applicable for the assessment.

##### Parameter 3 – Therapeutic effect in the field (effectiveness)

As currently there is no treatment available for IPN, Parameter 3 is not applicable for the assessment.

#### *Feasibility*

##### Parameter 4 – Way of administration

As currently there is no treatment available for IPN, Parameter 4 is not applicable for the assessment.

### 3.1.4.4. Article 7(d)(iv) Biosecurity measures

#### *Availability*

##### Parameter 1 – Available biosecurity measures

As mentioned previously, IPNV may be transmitted via eggs, fry, anthropogenic fomites, different animals and water. In order to reduce significantly the prevalence of the virus, control measures should consist of a combination of strict biosecurity measures in freshwater and importation of IPNV-free ova/smolt (Ruane et al., 2007). It is essential to obtain stock from IPNV-free sources and to use protected water supplies whenever new fish are introduced. IPNV is very difficult to be inactivated; however, Ruane et al. (2007) and WOA (2003) cited in Dhar et al. (2017) described that disinfectants with the following properties have been shown to be useful to inactivate IPNV: chlorine (30 ppm for 5 min) and iodophor-based disinfectants, alkaline solutions > pH 12, temperatures > 60°C, formalin based (3% for 5 min). Water may be treated for virus inactivation with UV (> 1200 J m<sup>-2</sup>) or ozone (0.1–0.2 mg L<sup>-1</sup>) (Graham, 2006). In IPNV-free areas, testing of fish eggs and exclusion of IPNV-infected eggs are required, as iodophor treatment is not effective as a means of control (McAllister, 1983).

Previously, WOA recommended to establish a programme of individual parent testing, which promoted the immediate disposal of ova from IPN-positive parents as soon as laboratory results were made available. Salmon brood stock testing data from 2004 to 2006 in Ireland, where the detection of the IPNV was based on the testing of sample pools (ovarian fluid, milt or kidney/brain/heart) between 1–10 fish using cell culture followed by a confirmatory ELISA test, showed that the highest number of positive isolations were observed in the organ samples submitted for testing (Ruane et al., 2007).

#### *Effectiveness*

##### Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction

A site-specific biosecurity and water quality improvement plan introduced into the Marine Harvest Norway, Bessaker site in 2000–2001 resulted in the successful eradication of the virus (G. Ritchie, Marine Harvest, pers. comm. cited in Ruane et al., 2007).



Rexhepi et al. (2014) demonstrated that the application of good sanitary practices helps to reduce IPN outbreaks in rainbow trout farms. This was shown by comparing results from a study conducted before and after preventive measures such as egg disinfection, sanitation before introducing a new fish stock and use of pathogen-free water (IPNV-positive fish farms rates of 53.8% and 22.2%, respectively).

#### *Feasibility*

##### Parameter 3 – Feasibility of biosecurity measure

Holding fish while awaiting test results relies on having suitable biosecurity systems to hold the fish in a sustainable manner. Such systems must have sufficient space to hold the stock, feed the fish and maintain the environmental quality of the water they are held in (EFSA AHAW Panel, 2017b).

#### **3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products**

#### *Availability*

##### Parameter 1 – Available movement restriction measures

Due to its widespread, often endemic occurrence in salmonid populations, WOAHA has delisted the disease, which eliminated official movement restrictions and compulsory culling policies. However, as stipulated in Commission Implementing Decision (EU) 2022/1188, areas regarded as being partly free of the disease (areas in Denmark, Finland, Slovenia and Sweden) are allowed to apply restrictions on the import of fish from countries with a lesser health status with respect to IPNV. To date, only parts of EU countries have been recognised as IPN-free. Since farmed fish are likely to be the most important reservoir of IPNV, and carriers are capable of shedding sufficient virus to establish an infection in exposed populations, transfers of farmed fish between farms are therefore one of the highest risks in the introduction of IPNV and one of the most effective ways of introducing the virus into a farm. It is therefore recommended to conduct a risk assessment before any movement of live fish takes place onto a farm (Scottish Government, 2019; Sommerset et al., 2022).

#### *Effectiveness*

##### Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread

Ruane et al. (2007) indicated in 2007 that all clinical outbreaks of IPN in Ireland had been associated with imports and that if the imports from infected sites were stopped, the disease could potentially be eradicated. A practical solution to the problem would be the screening of broodstock/ova for IPNV and fish movements.

#### *Feasibility*

##### Parameter 3 – Feasibility of restriction of animal movement

No information was found in the publications.

#### **3.1.4.6. Article 7(d)(vi) Killing of animals**

#### *Availability*

##### Parameter 1 – Available methods for killing animals

As described in the aquatic code of the World Organisation for Animal Health (Chapters 7.3 and 7.4) (WOAHA, 2022), several killing methods exist such as using an overdose of an anaesthetic agent or mechanical killing methods. The killing method should be selected taking into consideration fish welfare and biosecurity requirements, as well as the safety of the personnel.

EFSA (EFSA AHAW Panel, 2009) reported the following methods used for emergency slaughter: pharmacological, electrical and maceration. The brood stock is usually killed by the application of pharmacological methods before destruction.

#### *Effectiveness*

##### Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping spread of the disease

Killing and removal of fish from an infected farm effectively eliminates further contamination of the environment and thus is effective in reducing the spread of the disease via water or fomites

transmission. However, as described in previous sections, the environment will remain contaminated if no further biosecurity measures are taken (EFSA AHAW Panel, 2017b). Eriksson-Kallio et al. (2016) reported an example of a rainbow trout farm in Finland that, despite applying eradication measures consisting of the destruction of fish, thorough mechanical cleaning and disinfection of tanks and equipment followed by fallowing for 1 month, the farm was still infected with IPNV the following year.

### *Feasibility*

#### Parameter 3 – Feasibility of killing animals

Killing using an overdose of an anaesthetic (e.g. MS222) administered to fish kept in small volumes of water is the most feasible method available. Detailed protocols setting tank sizes and dosing per biomass of fish are not publicly available. Percussion stunning using a 'priest' followed by exsanguination or evisceration is most suitable for small numbers of fish. Electrical stunning is feasible if the appropriate equipment is available but is not widely used. Studies on fish welfare before slaughter have concluded that many of the traditional systems used to stun fish including CO<sub>2</sub> narcosis are not acceptable in terms of welfare, as they cause stress before death than could be avoided. Exposure to water saturated with CO<sub>2</sub> triggers aversive struggling and escape responses for several minutes before immobilisation, whereas in fish exposed to an electric current, immobilisation is close to instant (Gräns et al., 2016). A knowledge gap exists as there are no published data comparing rates of culling by different methods (EFSA AHAW Panel, 2017b).

#### **3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products**

### *Availability*

#### Parameter 1 – Available disposal option

Assuming that moribund and dead fish shed more IPNV than carrier fish, prompt removal and safe disposal of mortalities is a simple husbandry measure that can help prevent the spread of disease. Measures will include the daily inspection of tanks and cages for evidence of dead or moribund fish and the use of systems for removing mortalities from fish farm tanks and cages and their safe disposal (e.g. by composting or ensiling) (FHL and VESO, 2003).

An alkaline hydrolysis method in which macerated fish mortalities are exposed to high pH (> 13) for 7 days inactivates high titres of IPNV and is recommended as a biosecurity treatment method for fish by-products that contain fish pathogens (Dixon et al., 2012b). However, ensiling (a method of carcass disposal that involves lowering the pH to < 4) was determined to not be a biosecurity method for disposal of fish mortalities (Smail et al., 1993a; Dixon et al., 2012a; Canadian Food Inspection Agency, 2020).

### *Effectiveness*

#### Parameter 2 – Effectiveness of disposal option

No information was found in the publications.

### *Feasibility*

#### Parameter 3 – Feasibility of disposal option

No information was found in the publications.

#### **3.1.4.8. Article 7(d)(viii) Selective breeding; genetic resistance to infection**

### *Availability*

#### Parameter 1 – Available breeds resistant to the pathogen

As past research has demonstrated that there is genetic variation in resistance to IPNV in both Atlantic salmon and rainbow trout populations (Storset et al., 2007; Guy et al., 2009), breeding companies have gone into selectively breeding fish resistant to IPNV since the beginning of the 2000s. This large-scale production of IPN-resistant salmon for the aquaculture industry has been made possible by genetic mapping of the (QTL) affecting disease resistance against IPNV that explains 80–100% of genetic variation in fish susceptibility to IPNV at the first feeding fry (freshwater) and post-smolt (seawater) stages, in two separate populations, Scotland and Norway (Houston et al., 2008; Moen et al., 2009; Flores-Mara et al., 2017; Tapia et al., 2022). First, mutations in the epithelial

cadherin gene (*cdh1*) were identified as the likely causative genetic variation for IPNV resistance in Atlantic salmon (Houston et al., 2008, 2010; Moen et al., 2009, 2015; Rodríguez et al., 2019; Hillestad et al., 2021). Subsequent work however implicates the Nedd-8 activating enzyme gene as the underlying candidate gene (Pavelin et al., 2021).

### *Effectiveness*

#### Parameter 2 – Effectiveness of having resistant breeds

Selective breeding for resistance to clinical disease in IPNV has proven to be a highly effective strategy for the salmon aquaculture industry, with a single QTL conferring high resistance to disease. An important element of selective breeding in this instance is that resistance is conferred on all stages of Atlantic salmon that are susceptible to the disease (i.e. first feeding fry and post-smolts) (FHL and VESO, 2003). In Norway, IPN has been managed well for many years by using QTL selection combined with the systematic extinction of house strains. Following the inclusion of this QTL into the breeding programmes, the salmon industry witnessed a sharp decline in the number of IPN outbreaks throughout Norway, dropping from 223 to only 19 reported cases from 2009 to 2019 (~ 90% decrease) (Munang'andu et al., 2016; Sommerset et al., 2020). An independent economic analysis (Economic impact report from AbacusBio Ltd cited in Research Excellence Framework, 2021) showed that between August 2013 and July 2020, marker-assisted selection for resistance to IPN had nearly eradicated this disease from farmed salmon stocks, averting the death of 8,000,000–18,000,000 salmon across Chile, Norway and Scotland, thus increasing salmon production by between 36,800 and 79,600 tonnes across the three countries. The total value of this increased production, after accounting for feeding costs, has been between £108,000,000 and £234,000,000 to the global salmon farming industry.

However, in 2019, a new variant of IPNV was identified from a field outbreak in western Norway that had caused significant mortality, even in genetically resistant salmon. Although the overall the number of IPN detections has not increased since then, the reports indicate that efforts must be made to map mechanisms for IPN QTL salmon for protection against the new IPNV variant (Hillestad et al., 2021; Sommerset et al., 2022).

### *Feasibility*

#### Parameter 3 – Feasibility of having these resistant breeds

A selective breeding study was initiated in 1996 to assess the feasibility of selecting salmon resistant to IPNV and included a series of field and experimental trials challenging known full-sib Atlantic salmon families with IPNV. A total of 376,541 seawater and 28,182 freshwater fish subjected to IPNV challenge covering a 14-year period in 17 separate locations across seven sites. The results of the study indicated that selecting salmon for resistance to both seawater and freshwater IPNV challenge was clearly feasible, and that adverse effects of selection for other important production traits were not expected (Guy, 2011). Experimental challenge of salmon fry (freshwater) has indicated that those having both sire and dam carrying the resistance QTL haplotype showed 0% mortality, while those with a single resistant parent showed 1–2% mortality. In contrast, fully susceptible fish showed a mortality of 69% (Houston et al., 2010). The feasibility of selective breeding has now been clearly demonstrated by the decline in the number of IPN outbreaks experienced by countries that have been applying the technology in salmon aquaculture such as Norway (Hillestad et al., 2021; Research Excellence Framework, 2021).

Next to what has been done in Atlantic salmon, Rodríguez et al. (2019) have shown that given the heritability for resistance values calculated using genomic information in rainbow trout (time to death: 0.53 and binary survival: 0.82), the selection to improve resistance to IPN in that species would also be feasible.

### **3.1.5. Article 7(e) The impact of disease prevention and control measures**

#### **3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy as a whole**

##### Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)

Important principles of disease control, like the elimination of vertical transmission and spread of IPNV through infected broodstock and persistently infected fingerlings or smolt, are considered of



major importance for the spread of the virus. In Norway, no one has analysed the total implementation of these principles. Reasons for this are mainly economic and practical: Costs connected to extensive test programmes are enormous and the benefit uncertain (FHL and VESO, 2003).

Ruane et al. (2007) pinpointed that the smaller market for aquatic animals compared with the much larger terrestrial animal market means that the costs of producing inactivated viral vaccines are relatively high. In addition to this, oral vaccines against fish viral diseases, which would provide a stress-free method of vaccinating fish of any age, are rare as high costs are associated with developing carrier compounds to protect the vaccine against the digestive system.

#### Parameter 2 – Cost of eradication (culling, compensation)

When IPNV was detected in Finland inland farms in 2012–2013, the estimated eradication costs outweighed the expected benefits, and eradication of IPNV from continental Finland was not considered feasible. Finnish authorities decided to limit the national control programme to IPNV strains belonging to Genogroup 5, which are known to be highly pathogenic, causing mortality and clinical disease (Eriksson-Kallio et al., 2016).

#### Parameter 3 – Cost of surveillance and monitoring

No information was found in the publications.

#### Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product

No information was found in the publications.

#### Parameter 5 – Importance of the disease for the affected sector (% loss or euro lost compared with business amount of the sector)

IPN was considered a serious viral disease in salmon production. It is economically important due to its lethality for salmonid fry in freshwater production, and in post-smolts after transfer to seawater (Ariel and Olesen, 2001; Dhar et al., 2017). In 1998, in Norway, before the wide use of selective breeding in the salmon industry, the economic losses related to IPN were estimated to exceed €12 million (Munro and Midtlyng, 2011). A survey conducted in 2001 in Scotland showed an average loss due to IPN equated to an immediate cash value of £2 million, and this was considered as an underestimation (Ruane et al., 2007). The potential value of the fish lost due to IPN outbreak in salmon rearing units in Ireland in 2006 was estimated at €26–31 million (Ruane et al., 2007). The effect of IPN on salmon production is particularly serious as it can also cause the death of smolts shortly after they are put to sea. Since these smolts are half to 2 years old when they are put to sea, they represent a considerable investment, so their loss is economically serious (Murray et al., 2004).

### **3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control measures**

Contrary to chemotherapeutics that may cause safety concerns, vaccination contributes to environmental, social and economic sustainability in global aquaculture, and is therefore generally well accepted as an effective method for preventing infectious diseases such as IPN (Ma et al., 2019b). Conversely, the use of selective breeding and genome-editing approaches to enhance infectious disease resistance in aquaculture may raise safety and ethical concerns. However, a recent survey found that the majority of Norwegian consumers were positive about using gene editing in Norwegian agriculture and aquaculture for purposes that are perceived to promote societal benefit and sustainability, such as improving animal health (Norwegian Biotechnology Advisory Board, 2020). In a survey conducted in Norway by VESO in 2003, only a minority among fish health personnel and fish farmers agreed that the IPN problem would have been more prominent without the current management. The most common remark, when asked to propose suggestions for a future strategy, was that broodstock control should have been stricter (FHL and VESO, 2003).

### 3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals

#### Parameter 1 – Welfare impact of control measures on domestic/farmed animals

Oil-adjuvanted vaccines delivered by intraperitoneal injection may have important side effects on fish welfare such as pain, appetite loss, tissue adhesions around the injection site, pigmentation and intra peritoneum granuloma (Maria Poli, 2009). Therefore, as stated previously, oral vaccination is the preferred method from a fish farmer's perspective as it is stress-free.

In addition, handling and transporting fish for testing, quarantine or while awaiting test results are stressful events and require the availability of suitable biosecurity systems to maintain the fish. Such systems must have sufficient space to hold the stock, feed the fish and maintain the environmental quality of the water they are held in (EFSA AHAW Panel, 2017b).

EFSA (EFSA AHAW Panel, 2009) assessed the welfare aspects of killing farmed Atlantic salmon and reported that pre-slaughter crowding and pumping would subject the fish to metabolic and handling stress. There is also always a certain risk of poor welfare involved when live fish are transported. When fish are transported under good conditions (open transport), then the fish may recover from crowding and handling during the transport. As the fish are supplied to the stunning or killing unit operation, there is a high risk that salmon is subjected to metabolic stress, handling stress and poor welfare (exhaustion) prior to slaughter. There is some risk of poor welfare when applying electrical stunning in a water (batch) system mainly due to mis-stunning or electrical exhaustion. There is a high risk of poor welfare when benzocaine and metacaine are used in seawater to kill salmon. Using mills for maceration, fish should be previously stunned, and fish should then be instantaneously killed.

#### Parameter 2 – Wildlife depopulation as a control measure

Not applicable.

### 3.1.5.4. Article 7(e)(iv) The environment and biodiversity

#### *Environment*

#### Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments (soil, water, feed, manure)

The use of pharmacological products in the context of fish emergency slaughter such as anaesthetics might affect the environment if discharged into the surrounding water bodies. Yet, the use of anaesthetics in the context of aquaculture is generally considered to be of little risk to the environment, since these products are used infrequently and in low doses, thus limiting the potential for environmental damage (Burridge et al., 2010).

#### Parameter 2 – Mortality in wild species

See the Section 3.1.2.4 on the Impact of the disease on biodiversity and the environment Parameter 2.

## 3.2. Assessment of infectious pancreatic necrosis according to Article 5 criteria of AHL on its eligibility to be listed

### 3.2.1. Detailed outcome on Article 5 criteria

In Table 9 and Figure 2, the results of the expert judgement on the Article 5 criteria of the AHL for infectious pancreatic necrosis are presented.


The distribution of the individual answers (probability ranges) provided by each expert for each criterion is reported in Appendix A.

**Table 9:** Outcome of the expert judgement on Article 5 criteria

Criteria to be met by the disease:		Outcome			
		Median range (%)	Criterion fulfilment	Number of NA	Number of experts
According to the AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria					
A(i)	The disease is transmissible	99–100	Fulfilled	0	15
A(ii)	Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in the Union	99–100	Fulfilled	0	15
A(iii)	The disease causes negative effects on animal health or poses a risk to public health due to its zoonotic character	90–100	Fulfilled	0	15
A(iv)	Diagnostic tools are available for the disease	95–100	Fulfilled	0	15
A(v)	Risk-mitigating measures and, where relevant, surveillance of the disease are effective and proportionate to the risks posed by the disease in the Union	50–90	Uncertain	1	15
<b>At least one criterion to be met by the disease:</b>					
In addition to the criteria set out above at point A(i)–A(v), the disease needs to fulfil at least one of the following criteria					
B(i)	The disease causes or could cause significant negative effects in the Union on animal health, or poses or could pose a significant risk to public health due to its zoonotic character	66–90	Fulfilled	0	15
B(ii)	The disease agent has developed resistance to treatments which poses a significant danger to public and/or animal health in the Union	NA	NA	15	15
B(iii)	The disease causes or could cause a significant negative economic impact affecting agriculture or aquaculture production in the Union	66–95	Fulfilled	0	15
B(iv)	The disease has the potential to generate a crisis, or the disease agent could be used for the purpose of bioterrorism	1–5	Not fulfilled	0	15
B(v)	The disease has or could have a significant negative impact on the environment, including biodiversity, of the Union	10–33	Not fulfilled	0	15

NA: not applicable. Green is used for fulfilled, red for not fulfilled and orange for uncertain.

In Figure 2, the outcome of the expert judgement is graphically shown together with the estimated overall probability of the infectious pancreatic necrosis meeting the criteria of Article 5 on the eligibility to be listed.



**Figure 2:** Outcome of the expert judgement on Article 5 criteria and overall probability of infectious pancreatic necrosis on eligibility to be listed

### 3.2.2. Reasoning for uncertain outcome on Article 5 criteria

**Criterion A(v)** (risk-mitigating measures and, where relevant, surveillance of the disease are effective and proportionate to the risks posed by the disease in the Union):

- The experience in risk mitigating measures and surveillance activities to control IPN is coming from some regions in Scandinavian Countries (e.g. Norway) and it is uncertain if they can be effective in other EU countries.
- The IPNV is widespread in the EU, and therefore, it is uncertain how effective the surveillance activities and mitigation measures may be to control the disease. As a result, there is also uncertainty around the cost-benefit of their implementation. On the other hand, surveillance activities and mitigation measures are necessary to follow up and eliminate the spread in case of IPNV occurrence in aquaculture.
- The effectiveness of the control measures is variable among different animal species. For example, for salmon, vaccines are available and breeds resistant to IPNV exist, so there is higher certainty for the effectiveness of the mitigation measures and surveillance activities while for rainbow trout, the uncertainty is higher since these options are not available.
- When IPN is introduced for the first time in a country or zone it becomes endemic, and usually it cannot be eradicated. Mitigation measure in that case is to establish IPN-free compartments based on certified IPN-free broodstocks.
- Genetic selection has proven an efficient practice for disease control in Norway.

### 3.2.3. Overall outcome on Article 5 criteria

As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article 5 if it fulfils all criteria of the first set from A(i) to A(v) and at least one of the second set of criteria from B(i) to B(v). According to the assessment methodology, a criterion is considered fulfilled when the lower bound of the median range lays above 66%.

According to the results shown in Table 9, infectious pancreatic necrosis complies with four criteria of the first set (A(i)–A(iv)), but there is uncertainty (50–90% probability) on the assessment on compliance with criterion A(v). Therefore, it is uncertain whether infectious pancreatic necrosis can be considered eligible to be listed for Union intervention as laid down in Article 5 of the AHL. The estimated overall probability range for the infectious pancreatic necrosis being eligible to be listed is 50–90% (see Figure 2).

### 3.3. Assessment of infectious pancreatic necrosis according to criteria in Annex IV for the purpose of categorisation as in Article 9 of the AHL

In Tables 10–14 and related graphs (Figures 3–5), the results of the expert judgement on infectious pancreatic necrosis according to the criteria in Annex IV of the AHL, for the purpose of categorisation as in Article 9, are presented.

The distribution of the individual answers (probability ranges) provided by each expert for each criterion are reported in Appendix A.


#### 3.3.1. Detailed outcome on Category A criteria

**Table 10:** Outcome of the expert judgement related to the criteria of Section 1 of Annex IV (Category A of Article 9)

Criteria to be met by the disease:		Outcome			
		Median range (%)	Criterion fulfilment	Number of NA	Number of experts
The disease needs to fulfil all of the following criteria					
1	The disease is not present in the territory of the Union or present only in exceptional cases (irregular introductions) or present in only in a very limited part of the territory of the Union	0–1	Not fulfilled	0	15
2.1	The disease is highly transmissible	33–66	Uncertain	1	15
2.2	There are possibilities of airborne or waterborne or vector-borne spread	95–99	Fulfilled	0	15
2.3	The disease affects multiple species of kept and wild animals or single species of kept animals of economic importance	95–100	Fulfilled	0	15
2.4	The disease may result in high morbidity and significant mortality rates	90–95	Fulfilled	0	15
<b>At least one criterion to be met by the disease:</b>					
In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria					
3	The disease has a zoonotic potential with significant consequences for public health, including epidemic or pandemic potential or possible significant threats to food safety	0–1	Not fulfilled	1	15
4	The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals	10–66	Uncertain	0	15
5(a)	The disease has a significant impact on society, with in particular an impact on labour markets	5–20	Not fulfilled	0	15
5(b)	The disease has a significant impact on animal welfare, by causing suffering of large numbers of animals	66–95	Fulfilled	0	15
5(c)	The disease has a significant impact on the environment, due to the direct impact of the disease or due to the measures taken to control it	5–33	Not fulfilled	0	15
5(d)	The disease has a significant impact in the long term on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds	5–33	Not fulfilled	0	15

NA: not applicable. Green is used for fulfilled, red for not fulfilled and orange for uncertain.





Category A: the probability of the disease to be categorised according to Section 1 of Annex IV of the AHL (overall outcome).

**Figure 3:** Outcome of the expert judgement on criteria of Section 1 of Annex IV and overall probability of the infectious pancreatic necrosis to be fitting in Category A of Article 9

### 3.3.1.1. Reasoning for the uncertain outcome on Category A criteria

#### Criterion 2.1 (The disease is highly transmissible):

- The difference between high and moderate-high transmissibility in the question is not clearly defined.  $R_0$  is more than 1, but less than 2.5, and these values do not suggest high transmissibility, although this may vary among virus genotypes and animal species.
- Reproduction of the disease under experimental conditions with non-invasive challenge methods is not efficient. Nevertheless, under field conditions, if infected fish are introduced in a farm, then the IPNV will be transmitted, and the farm will remain infected.
- Prevalence among farmed animals appears to be high, while it is low in wild animals. Morbidity varies considerably. Prevalence ranged from 1% to 100%.

**Criterion 4** (The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals):

- There is no evidence in the literature about the IPN impact on the economy of the Union overall to quantify the costs on animal health and production. In addition, there is gap of knowledge on the impact of IPN on the aquaculture sector in the Union.
- For the countries where IPN occur, and aquaculture is a significant economic sector, the financial impact can be considered significant. Nevertheless, this impact may vary based on the aquatic animal species, the implementation of vaccination and the use of resistant to IPN breeds (IPN-QTL).
- It may be possible to control IPN, but this has not been achieved in most countries; consequently, the economic significance is not deemed that important.

- The mortality can be very high and thus contribute to the impact on the economy, particularly, at a local level.


### 3.3.2. Detailed outcome on Category B criteria

**Table 11:** Outcome of the expert judgement related to the criteria of Section 2 of Annex IV (Category B of Article 9)

Criteria to be met by the disease:		Outcome			
		Median range (%)	Criterion fulfilment	Number of NA	Number of experts
The disease needs to fulfil all of the following criteria					
1	The disease is present in the whole or part of the Union territory with an endemic character and (at the same time) several Member States or zones of the Union are free of the disease	33–66	Uncertain	1	15
2.1	The disease is moderately to highly transmissible	90–95	Fulfilled	0	15
2.2	There are possibilities of airborne or waterborne or vector-borne spread	95–99	Fulfilled	0	15
2.3	The disease affects single or multiple species <sup>(a)</sup>	–	Fulfilled	0	15
2.4	The disease may result in high morbidity with in general low mortality	66–90	Fulfilled	0	15
<b>At least one criterion to be met by the disease:</b>					
In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria					
3	The disease has a zoonotic potential with significant consequences for public health, including epidemic potential or possible significant threats to food safety	0–1	Not fulfilled	1	15
4	The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals	10–66	Uncertain	0	15
5(a)	The disease has a significant impact on society, with in particular an impact on labour markets	5–20	Not fulfilled	0	15
5(b)	the disease has a significant impact on animal welfare, by causing suffering of large numbers of animals	66–95	Fulfilled	0	15
5(c)	The disease has a significant impact on the environment, due to the direct impact of the disease or due to the measures taken to control it	5–33	Not fulfilled	0	15
5(d)	The disease has a significant impact in the long term on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds	5–33	Not fulfilled	0	15

NA: not applicable. Green is used for fulfilled, red for not fulfilled and orange for uncertain.

(a): This is always fulfilled.



Category B: The probability of the disease to be categorised according to Section 2 of Annex IV of the AHL (overall outcome).

**Figure 4:** Outcome of the expert judgement on criteria of Section 2 of Annex IV and overall probability of the infectious pancreatic necrosis to be fitting in Category B of Article 9

**3.3.2.1. Reasoning for the uncertain outcome on Category B criteria**

**Criterion 1** (The disease is present in the whole or part of the Union territory with an endemic character and (at the same time) several Member States or zones of the Union are free of the disease):

- Since 2005, IPN is not a WOAHL-listed disease, and therefore, the reporting of IPN cases has decreased. Consequently, it is difficult to assess whether some countries or zones are free of IPNV or not. However, IPNV has been reported in the literature in at least 17 countries in the Union in the period 2014–2021, and three additional countries in Europe.
- Sweden and partially Finland (zones) are free from IPNV genotype 5 but not for all other genotypes. Denmark has IPN-free compartments and farms (broodstock farms) where high biosecurity is in place and the absence of IPN infection is very well documented (bi-annual testing for > 50 years).
- Although IPN is known to be endemic to salmonid farming in many areas around the world including Europe, and the disease is considered likely endemic in the parts of the Union not listed above, the current distribution of IPNV is not very clear.

**Criterion 4** (the disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals):

- There is no evidence in the literature about the IPN impact on the economy of the Union to quantify the costs on animal health and production. In addition, there is gap of knowledge on the impact of IPN on the aquaculture sector in the Union.



- For the countries where IPN occurs, and aquaculture is a significant economic sector the financial impact can be considered significant. Nevertheless, this impact may vary based on the aquatic animal species, the implementation of vaccination and the use of resistant to IPN breeds (IPN-QTL).


### 3.3.3. Detailed outcome on Category C criteria

**Table 12:** Outcome of the expert judgement related to the criteria of Section 3 of Annex IV (Category C of Article 9)

Criteria to be met by the disease:		Outcome			
		Median range (%)	Criterion fulfilment	Number of NA	Number of experts
The disease needs to fulfil all of the following criteria					
1	The disease is present in the whole OR part of the Union territory with an endemic character OR in <b>aquatic animals</b> several Member States or zones of the Union are free of the disease	90–99	Fulfilled	0	15
2.1	The disease is moderately to highly transmissible	90–95	Fulfilled	0	15
2.2	The disease is transmitted mainly by direct or indirect transmission <sup>(a)</sup>	–	Fulfilled	0	15
2.3	The disease affects single or multiple species <sup>(a)</sup>	–	Fulfilled	0	15
2.4	The disease may result in high morbidity and usually low mortality and often the most observed effect of the disease is production loss?	33–66	Uncertain	0	15
<b>At least one criterion to be met by the disease:</b>					
In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria					
3	The disease has a zoonotic potential with significant consequences for public health or possible significant threats to food safety	0–1	Not fulfilled	1	15
4	The disease has a significant impact on the economy of the Union, mainly related to its direct impact on certain types of animal production systems	33–90	Uncertain	0	15
5(a)	The disease has a significant impact on society, with in particular an impact on labour markets	5–20	Not fulfilled	0	14
5(b)	The disease has a significant impact on animal welfare, by causing suffering of large numbers of animals	66–95	Fulfilled	0	15
5(c)	The disease has a significant impact on the environment, due to the direct impact of the disease or due to the measures taken to control it	5–33	Not fulfilled	0	15
5(d)	The disease has a significant impact in the long term on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds	5–33	Not fulfilled	0	15

NA: not applicable. Green is used for fulfilled, red for not fulfilled and orange for uncertain.

(a): This is always fulfilled.



Category C: The probability of the disease to be categorised according to Section 3 of Annex IV of the AHL (overall outcome).

**Figure 5:** Outcome of the expert judgement on criteria of Section 3 of Annex IV and overall probability of IPN to be fitting in Category C of Article 9

**3.3.3.1. Reasoning for uncertain outcome on Category C criteria**

**Criterion 2.4:** (The disease may result in high morbidity and usually low mortality and often the most observed effect of the disease is production loss):

- The mortality ranges at farm level from 10% to 20% and can reach 70% in some cages. It is considered by the experts as significant and not low.
- There is uncertainty about the impact of IPN on production due to lack of scientific evidence. The impact on production is related to a range of different indicators in animal health and animal welfare. In the past, in infected farms, loss of production and low growth rates have not been assessed and there are no studies to estimate and quantify the impact of IPN.

**Criterion 4:** (The disease has a significant impact on the economy of the Union, mainly related to its direct impact on certain types of animal production systems):

- The impact to fish production varies depending on the type of the aquatic animals, the aquaculture practices, the implementation of vaccination or the use of resistant to IPN breeds (IPN-QTL).
- Major mortality rates have been observed, and the culling of large numbers of potentially infected fish has also been required.

### 3.3.4. Detailed outcome on Category D criteria

**Table 13:** Outcome of the expert judgement related to the criteria of Section 4 of Annex IV (Category D of Article 9)

Diseases in Category D <b>need to fulfil criteria of Sections 1, 2, 3 or 5 of Annex IV of the AHL and the following:</b>		Outcome			
		Median range (%)	Criterion fulfilment	Number of NA	Number of experts
D	The risk posed by the disease can be effectively and proportionately mitigated by measures concerning movements of animals and products in order to prevent or limit its occurrence and spread	66–95	Fulfilled	0	15

NA: not applicable. Green is used for fulfilled, red for not fulfilled and orange for uncertain.

### 3.3.5. Detailed outcome on Category E criteria (Table 14)

**Table 14:** Outcome of the expert judgement related to the criteria of Section 5 of Annex IV (Category E of Article 9)

Diseases in Category E <b>need to fulfil criteria of Sections 1, 2 or 3 of Annex IV of the AHL and/or the following:</b>		Outcome	
		Median range (%)	Fulfilment
E	Surveillance of the disease is necessary for reasons related to animal health, animal welfare, human health, the economy, society or the environment  (If a disease fulfils the criteria as in Article 5, thus being eligible to be listed, consequently Category E would apply.)	50–90	Uncertain

Green is used for fulfilled, red for not fulfilled and orange for uncertain.

### 3.3.6. Overall outcome on criteria in Annex IV for the purpose of categorisation as in Article 9


As from the legal text of the AHL, a disease is considered fitting in a certain category (A, B, C, D or E – corresponding to points (a) to (e) of Article 9(1) of the AHL) if it fulfils all criteria of the first set from 1 to 2.4 and at least one of the second set of criteria from 3 to 5(d), as shown in Tables 10–14. According to the assessment methodology, a criterion is considered fulfilled when the lower bound of the median range lays above 66%.

The overall outcome of the assessment on criteria in Annex IV of the AHL, for the purpose of categorisation of Infectious Pancreatic Necrosis as in Article 9, is presented in Table 15 and Figure 6.

**Table 15:** Outcome of the assessment on criteria in Annex IV of the AHL for the purpose of categorisation as in Article 9

Category	Article 9 criteria											D	Art 5
	1° set of criteria					2° set of criteria							
	1	2.1	2.2	2.3	2.4	3	4	5(a)	5(b)	5(c)	5(d)		
A	0–1	33–66	95–99	95–100	90–95	0–1	10–66	5–20	66–95	5–33	5–33		
B	33–66	90–95	95–99	–	66–90	0–1	10–66	5–20	66–95	5–33	5–33		
C	90–99	90–95	–	–	33–66	0–1	33–90	5–20	66–95	5–33	5–33		
D												66–95	
E													50–90

Green is used for fulfilled, red for not fulfilled and orange for uncertain.



**Figure 6:** Outcome of the expert judgement on criteria in Annex IV and overall probabilities for categorisation of IPN in accordance with Article 9

According to the assessment here performed, IPN complies with the following criteria of Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules referred to in points (a) to (e) of Article 9(1):

- 1) To be assigned to **Category A**, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and, according to the assessment, IPN complies only with four out of five criteria (2.1, 2.2 and 2.3). To be eligible for Category A, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5(a)–(d)) and IPN complies with 5 (b) criterion. Overall, it was assessed with 0–1% probability that IPN may be assigned to Category A according to criteria in Section 1 of Annex IV for the purpose of categorisation as in Article 9 of the AHL.
- 2) To be assigned to **Category B**, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and, according to the assessment, IPN complies only with four out of five criteria; 2.1, 2.2, 2.3 and 2.4. To be eligible for Category B, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5(a)–(d)) and IPN complies with 5 (b) criterion. Overall, it was assessed with 33–66% probability that IPN may be assigned to Category B according to criteria in Section 2 of Annex IV for the purpose of categorisation as in Article 9 of the AHL.
- 3) To be assigned to **Category C**, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and, according to the assessment, IPN complies with four out of five criteria; 1, 2.1, 2.2 and 2.3). To be eligible for Category C, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5(a)–(d)) and IPN complies with 5 (b) criterion. Overall, it was assessed with 33–66% probability that IPN may be assigned to Category C according to criteria in Section 3 of Annex IV for the purpose of categorisation as in Article 9 of the AHL.
- 4) To be assigned to **Category D**, a disease needs to comply with criteria of Sections 1, 2, 3 or 5 of Annex IV of the AHL and with the specific criterion D of Section 4. IPN does not comply

with criteria of Sections 1, 2, 3 or 5 of Annex IV of the AHL but complies with 66–95% probability with criterion D.

- 5) To be assigned to **Category E**, a disease needs to comply with criteria of Sections 1, 2 or 3 of Annex IV of the AHL, and/or the surveillance of the disease is necessary for reasons related to animal health, animal welfare, human health, the economy, society or the environment. The latter is applicable if a disease fulfils the criteria as in Article 5, for which the assessment is uncertain with 50–90% probability.

### 3.4. Assessment of infectious pancreatic necrosis according to Article 8 criteria of the AHL

In this section, the results of the assessment on the criteria of Article 8(3) of the AHL for infectious pancreatic necrosis are presented. The Article 8(3) criteria are about animal species to be listed, as it reads below:

*'3. Animal species or groups of animal species shall be added to the list if they are affected or if they pose a risk for the spread of a specific listed disease because:*

*a) they are susceptible to a specific listed disease, or scientific evidence indicates that such susceptibility is likely; or*

*b) they are vector species or reservoirs for that disease, or scientific evidence indicates that such role is likely.'*

For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from the relevant criteria of Article 7, i.e. the ones related to susceptible, vectors and reservoir species or routes of transmission, which cover also the possible role of biological or mechanical vectors.

According to the mapping, as presented in Table 5, Section 3.2, of the Scientific Opinion on the ad hoc methodology (EFSA AHAW Panel, 2017a), the animal species to be listed for infectious pancreatic necrosis according to the criteria of Article 8(3) of the AHL are as displayed in Table 16 (elaborated from information on animal species concerned reported in Section 3.1.1.1 of the present document).

The table contains all animal species in which infectious pancreatic necrosis has been described, but also those animal species from which only the infectious pancreatic necrosis virus itself has been isolated. The latter makes susceptibility to IPNV likely.



**Table 16:** Animal species to be listed for infectious pancreatic necrosis according to the criteria of Article 8

Type	Class	Order	Family	Genus/species	References
Susceptible	Actinopterygii	Anabantiformes	Channidae	<i>Channa striata</i>	Wattanavijarn et al. (1988)
		Anguilliformes	Anguillidae	<i>Anguilla anguilla</i>	Hudson et al. (1981)
				<i>Anguilla japonica</i>	Kim and Oh (2014)
		Clupeiformes	Clupeidae	<i>Brevoortia tyrannus</i>	Stephens et al. (1980), Nicholson and Caswell (1982)
		Cypriniformes	Cyprinidae	<i>Danio rerio</i>	Rud et al. (2020)
		Exociformes	Esocidae	<i>Esox lucius</i>	Ahne (1978), Hill and Way (1995)
		Gadiformes	Merlucciidae	<i>Merluccius merluccius</i>	Wallace et al. (2005)
			Gadidae	<i>Gadus morhua</i>	Duan et al. (2021), Jensen et al. (2009), Urquhart et al. (2009), Duan et al. (2021)
		Perciformes	Anarhichadidae	<i>Anarhichas minor</i>	Sommer et al. (2004)
			Moronidae	<i>Morone saxatilis</i>	Schutz et al. (1984)
			Moronidae	<i>Dicentrarchus labrax</i>	Bonami et al. (1983)
			Labridae	<i>Ctenolabrus rupestris</i>	Gibson et al. (1998)
		Pleuronectiformes	Pleuronectidae	<i>Limanda limanda</i>	Diamant et al. (1988), Munro et al. (2004), Wallace et al. (2008)
			Pleuronectidae	<i>Microstomus kitt</i>	Maj-Paluch et al. (2020)
			Pleuronectidae	<i>Pleuronectes platessa</i>	Wallace et al. (2008)
			Pleuronectidae	<i>Hippoglossus hippoglossus</i>	Biering et al. (1994), Rodger and Frerichs (1997)
			Scophthalmidae	<i>Scophthalmus maximus</i>	Novoa et al. (1993)
		Salmoniformes	Salmonidae	<i>Coregonus lavaretus</i>	Castric et al. (1987), Mortensen et al. (1993), Duan et al. (2021)
				<i>Oncorhynchus clarkii</i>	Blake et al. (2001)
				<i>Oncorhynchus gorbuscha</i>	Hill and Way (1995)
				<i>Oncorhynchus keta</i>	Jeon et al. (2011)
				<i>Oncorhynchus kisutch</i>	Lopez-Lastra et al. (1994), Eissler et al. (2011)
				<i>Oncorhynchus mykiss</i>	Blake et al. (2001), Bebak and McAllister (2009)
				<i>Oncorhynchus rhodurus</i>	Jung et al. (1999), Zhang and Suzuki (2003)
				<i>Oncorhynchus tshawytscha</i>	Davies et al. (2010)
				<i>Salmo salar</i>	Blake et al. (2001), Cutrín et al. (2004), Shivappa et al. (2004)
				<i>Salmo trutta</i>	Rexhepi et al. (2011), Ulrich et al. (2018)
<i>Salvelinus alpinus</i>	Blake et al. (2001)				
<i>Salvelinus fontinalis</i>	Bootland et al. (1991); Blake et al. (2001)				

Type	Class	Order	Family	Genus/species	References
Vector				<i>Salvelinus namaycush</i>	Maj-Paluch et al. (2020)
	Branchiopoda	Diplostraca	Daphniidae	<i>Daphnia magna</i>	Mortensen et al. (1993)
	Copepoda	Siphonostomatoida	Caligidae	<i>Lepeophtheirus salmonis</i>	Johnson et al. (2004)
	Malacostraca	Decapoda	Astacidae	<i>Astacus astacus</i>	Halder and Ahne (1988)
			Penaeidae	<i>Penaeus japonicus</i>	Mortensen et al. (1993)
Carcinidae			<i>Carcinus maenas</i>	Mortensen et al. (1993)	
Bivalvia	Mytilida	Mytilidae	<i>Mytilus edulis</i>	Molloy et al. (2013)	
IPNV has been isolated from piscivorous bird species that frequent fish farms for feeding e.g. <i>Ardea cinerea</i> , <i>Chroicocephalus ridibundus</i> , Mink may be a possible vector (Sonstegard and McDermott, 1972), as IPNV can be recovered from mink faeces 1 week after experimental infection.					
Reservoir	Actinopterygii	Carangiformes	Carangidae	<i>Seriola dumerili</i>	Kusuda et al. (1993)
				<i>Seriola quinqueradiata</i>	Sorimachi and Hara (1985)
				<i>Seriola lalandi</i>	Kusuda et al. (1993)
	Cypriniformes	Cyprinidae		<i>Abramis brama</i>	Adair and Ferguson (1981)
				<i>Carassius auratus</i>	Adair and Ferguson (1981)
				<i>Luciobarbus graellsii</i>	Ortega (1993)
	Gadiformes	Gadidae		<i>Merlangius merlangus</i>	Possible reservoirs Wallace et al. (2008)
				<i>Pollachius virens</i>	Possible reservoirs Wallace et al. (2008)
	Perciformes	Cichlidae		<i>Oreochromis mossambicus</i>	Mulei et al. (2018)
				<i>Symphysodon discus</i>	Adair and Ferguson (1981)
		Sparidae			<i>Pagrus pagrus</i>
	Pleuronectiformes				Pleuronectidae
		<i>Platichthys flesus</i>	Possible reservoirs Wallace et al. (2008)		
		Soleidae			
	<i>Solea solea</i>				Hill and Way (1995)
	Salmoniformes	Salmonidae		<i>Hucho hucho</i>	IPNV isolation from asymptomatic Ahne (1980), Hill and Way (1995)
				<i>Thymallus thymallus</i>	IPNV isolation from asymptomatic Ahne (1980), Hill and Way (1995)
	Scorpaeniformes	Triglidae		<i>Eutrigla gurnardus</i>	Possible reservoirs Wallace et al. (2008)
	Bivalvia	Unionida	Unionidae	<i>Anodonta cygnea</i>	Rud et al. (2020)

Classification of susceptible, vector and reservoir species has been updated to the currently accepted scientific names according to GBIF (Global Biodiversity Information Facility), WoRMS (World Register of Marine Species) and ITIS (Integrated Taxonomic Information System) taxonomy database.

## 4. Conclusions

The AHAW Panel emphasises that the assessment of impacts, as well as prevention and control measures, related to IPN using the criteria as laid down in Articles 5 and 9 of the AHL is particularly challenging in.

**TOR 1:** *For each of the diseases referred to above, an assessment, taking into account the criteria laid down in Article 7 of the AHL, on the eligibility of the disease to be listed for Union intervention as laid down in Article 5(3) of the AHL;*

It is uncertain 50–90% probability (from “about as likely as not” to “likely”) whether IPN can be considered eligible to be listed for Union intervention as laid down in Article 5 of the AHL.

**TOR 2(a):** *For each of the diseases an assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9(1) of the AHL;*

- The AHAW Panel considered with 0–1% probability (‘almost impossible’) that IPN meets the criteria as in Section 1 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in point (a) of Article 9(1) of the AHL.
- The AHAW Panel was uncertain (33–66% probability, ‘about as likely as not’) whether IPN meets the criteria as in Section 2 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in point (b) of Article 9(1) of the AHL.
- The AHAW Panel was uncertain (33–66% probability, ‘about as likely as not’) whether IPN meets the criteria as in Section 3 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in point (c) of Article 9(1) of the AHL.
- The AHAW Panel was uncertain (50–90% probability; from ‘about as likely as not’ to ‘likely’) whether IPN meets the criteria as in Section 4 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in point (d) of Article 9(1) of the AHL.
- The AHAW Panel was uncertain (50–90% probability; from ‘about as likely as not’ to ‘likely’) whether IPN meets the criteria as in Section 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in point (e) of Article 9(1) of the AHL.

**TOR 2(b):** *For each of the diseases, a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.*

The animal species that can be considered to be listed for IPN according to Article 8(3) of the AHL are reported in Table 16 in Section 3.4 of the present document.

The AHAW Panel highlights that even though the assessment on IPN is inconclusive regarding its eligibility to be listed for Union intervention, specific activities and initiatives should be considered based on the epidemiological situation such as:

- surveillance activities to provide information on the geographical distribution of the IPNV
- research to enlighten areas where there is knowledge gaps or limitations and help to better understand the impact of IPNV on animal health and welfare in EU.

## References

- Adair BM and Ferguson HW, 1981. Isolation of infectious pancreatic necrosis (IPN) virus from non-salmonid fish. *Journal of Fish Diseases*, 4, 69–76. <https://doi.org/10.1111/j.1365-2761.1981.tb01110.x>
- Ahmadivand S, Weidmann M, El-Matbouli M and Rahmati-Holasoo H, 2020. Low pathogenic strain of infectious pancreatic necrosis virus (IPNV) associated with recent outbreaks in Iranian trout farms. *Pathogens*, 9. <https://doi.org/10.3390/pathogens9100782>
- Ahne W, 1978. Isolation and characterization of infectious pancreatic necrosis virus from pike (*Esox lucius*). *Archives of Virology*, 58, 65–69. <https://doi.org/10.1007/bf01315537>
- Ahne W, 1980. Occurrence of infectious pancreatic necrosis virus (IPN) in different fish species. *Berliner und Munchener Tierarztliche Wochenschrift*, 93, 14–16.
- Ahne W, 1983. Presence of infectious pancreatic necrosis virus in the seminal fluid of rainbow trout, *Salmo gairdneri* Richardson. *Journal of Fish Diseases*, 6, 377. <https://doi.org/10.1111/j.1365-2761.1983.tb00089.x>
- Ahne W, 1985. Studies on transmission of infectious pancreatic necrosis virus via eyed eggs and sexual products of salmonid fish. In: Ellis AE (ed.). *Fish and shellfish pathology*. Academic Press, London. pp. 262–270.

- Ahne W and Thomsen I, 1986. Infectious pancreatic necrosis: detection of virus and antibodies in rainbow trout IPNV-carrier (*Salmo gairdneri*). Zentralblatt für Veterinärmedizin. Reihe B. Journal of veterinary medicine. Series B, 33, 552–554. <https://doi.org/10.1111/j.1439-0450.1986.tb00067.x>
- Ariel E and Olesen N, 2001. Finfish in aquaculture and their diseases-A retrospective view on the European Community. *Proceedings of the 10th International Conference on Diseases of Fish and Shellfish*, Dublin, Ireland.
- Bang Jensen B and Kristoffersen AB, 2015. Risk factors for outbreaks of infectious pancreatic necrosis (IPN) and associated mortality in Norwegian salmonid farming. *Diseases of Aquatic Organisms*, 114, 177–187. <https://doi.org/10.3354/dao02867>
- Barja J, Toranzo A, Lemos M and Hetrick F, 1983. Influence of water temperature and salinity on the survival of IPN and IHN viruses [infectious pancreatic necrosis virus, infectious haematopoietic necrosis virus]. Available online: <https://eafp.org/>
- Bebak J, McAllister P and Smith G, 1998. Infectious pancreatic necrosis virus: transmission from infectious to susceptible rainbow trout fry. *Journal of Aquatic Animal Health*, 10, 287–293. [https://doi.org/10.1577/1548-8667\(1998\)010<0287:IPNVTF>2.0.CO;2](https://doi.org/10.1577/1548-8667(1998)010<0287:IPNVTF>2.0.CO;2)
- Bebak J and McAllister PE, 2009. Continuous exposure to infectious pancreatic necrosis virus during early life stages of rainbow trout, *Oncorhynchus mykiss* (Walbaum). *Journal of Fish Diseases*, 32, 173–181. <https://doi.org/10.1111/j.1365-2761.2008.00974.x>
- Benkaroun J, Muir KF, Allshire R, Tamer C and Weidmann M, 2021. Isolation of a new infectious pancreatic necrosis virus (IPNV) variant from a fish farm in Scotland. *Viruses*, 13. <https://doi.org/10.3390/v13030385>
- Biering E, Nilsen F, Rødseth OM and Glette J, 1994. Susceptibility of Atlantic halibut *Hippoglossus hippoglossus* to infectious pancreatic necrosis virus. <https://doi.org/10.3354/dao020183>
- Blake S, Ma JY, Caporale DA, Jairath S and Nicholson BL, 2001. Phylogenetic relationships of aquatic birnaviruses based on deduced amino acid sequences of genome segment A cDNA. *Diseases of Aquatic Organisms*, 45, 89–102. <https://doi.org/10.3354/dao045089>
- Bonami JR, Cousserans F, Weppe M and Hill BJ, 1983. Mortalities in hatchery-reared sea bass fry associated with a birnavirus. *Bulletin of the European Association of Fish Pathologists*, 3, 41.
- Bootland LM, Dobos P and Stevenson RM, 1991. The IPNV carrier state and demonstration of vertical transmission in experimentally infected brook trout. *Diseases of Aquatic Organisms*, 10, 13–21. <https://doi.org/10.3354/DAO10013>
- Bowden TJ, Smail DA and Ellis AE, 2002. Development of a reproducible infectious pancreatic necrosis virus challenge model for Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases*, 25, 555–563. <https://doi.org/10.1046/j.1365-2761.2002.00402.x>
- Bruno D, 2004. Changes in prevalence of clinical infectious pancreatic necrosis among farmed Scottish Atlantic salmon, *Salmo salar* L. between 1990 and 2002. *Aquaculture*, 235, 13–26. <https://doi.org/10.1016/j.aquaculture.2003.11.035>
- Bucke D, Finlay J, McGregor D and Seagrave C, 1979. Infectious pancreatic necrosis (IPN) virus: its occurrence in captive and wild fish in England and Wales. *Journal of Fish Diseases*, 2, 549–553. <https://doi.org/10.1111/j.1365-2761.1979.tb00416.x>
- Burridge L, Weis JS, Cabello F, Pizarro J and Bostick K, 2010. Chemical use in salmon aquaculture: a review of current practices and possible environmental effects. *Aquaculture*, 306, 7–23. <https://doi.org/10.1016/j.aquaculture.2010.05.020>
- Büyükekiz AG, Altun S, Hansen EF, Saticioglu IB, Duman M, Markussen T and Rimstad E, 2018. Infectious pancreatic necrosis virus (IPNV) serotype Sp is prevalent in Turkish rainbow trout farms. *Journal of Fish Diseases*, 41, 95–104. <https://doi.org/10.1111/jfd.12675>
- Canadian Food Inspection Agency, 2020, online. Facts about infectious pancreatic necrosis. Available online: <https://inspection.canada.ca/animal-health/aquatic-animals/diseases/reportable-diseases/infectious-pancreatic-necrosis/fact-sheet/eng/1330099413455/1330099555496>
- Candan A, 2002. First report on the diagnosis of infectious pancreatic necrosis (IPN) based on reverse transcription polymerase chain reaction (RT-PCR) in Turkey. 0108-0288. pp. 45–47. Available online: <https://eafp.org/>
- Castric J, Baudin-Laurencin F, Coustans MF and Auffret M, 1987. Isolation of infectious pancreatic necrosis virus, Ab serotype, from an epizootic in farmed turbot, *Scophthalmus maximus*. *Aquaculture*, 67, 117–126. [https://doi.org/10.1016/0044-8486\(87\)90016-0](https://doi.org/10.1016/0044-8486(87)90016-0)
- Centre for Environment Fisheries and Aquaculture Science, 2021, online. International database on aquatic animal diseases. Available online: <https://www.cefas.co.uk/international-database-on-aquatic-animal-diseases/>
- Chen L, 2017. Studies of oral vaccination against infectious pancreatic necrosis in Atlantic salmon: focus on antigen production, antigen kinetics, and immune responses.
- Chong RS-M, 2022. Infectious pancreatic necrosis In: *Aquaculture Pathophysiology*. Elsevier. pp. 165–175.
- Cutrín JM, Barja JL, Nicholson BL, Bandín I, Blake S and Dopazo CP, 2004. Restriction fragment length polymorphisms and sequence analysis: an approach for genotyping infectious pancreatic necrosis virus reference strains and other aquabirnaviruses isolated from northwestern Spain. *Applied and Environmental Microbiology*, 70, 1059–1067. <https://doi.org/10.1128/aem.70.2.1059-1067.2004>

- Damsgård B, Mortensen A and Sommer A-I, 1998. Effects of infectious pancreatic necrosis virus (IPNV) on appetite and growth in Atlantic salmon, *Salmo salar* L. *Aquaculture*, 163, 185–193. [https://doi.org/10.1016/S0044-8486\(98\)00242-7](https://doi.org/10.1016/S0044-8486(98)00242-7)
- Danish Veterinary and Food Administration, 2022, online. Aquatic animal health status. Available online: [https://www.foedevarestyrelsen.dk/english/Animal/AnimalHealth/Aquaculture/Aquatic\\_Animal\\_Health\\_Status/Pages/default.aspx](https://www.foedevarestyrelsen.dk/english/Animal/AnimalHealth/Aquaculture/Aquatic_Animal_Health_Status/Pages/default.aspx)
- Davies KR, McColl KA, Wang LF, Yu M, Williams LM and Crane MS, 2010. Molecular characterisation of Australasian isolates of aquatic birnaviruses. *Diseases of Aquatic Organisms*, 93, 1–15. <https://doi.org/10.3354/dao02278>
- Delmas B, Attoui H, Ghosh S, Malik YS, Mundt E, Vakharia VN and Consortium IR, 2019. ICTV virus taxonomy profile: Birnaviridae. *Journal of General Virology*, 100, 5–6. <https://doi.org/10.1099/jgv.0.001185>
- Dhar A, Manna S and Thomas Allnutt F, 2014. Viral vaccines for farmed finfish. *Virus Disease*, 25, 1–17. <https://doi.org/10.1007/s13337-013-0186-4>
- Dhar AK, Lapatra S, Orry A and F.C.T.A., 2017. Infectious Pancreatic Necrosis Virus (Woo PT and Cipriano RC, eds.). CABI.
- Diamant A, Smail D, McFarlane L and Thomson A, 1988. An infectious pancreatic necrosis virus isolated from common dab *Limanda limanda* previously affected with X-cell disease, a disease apparently unrelated to the presence of the virus. *Diseases of Aquatic Organisms*, 4, 223–227. <https://doi.org/10.3354/DAO004223>
- Dixon PF, Ngho GH, Stone DM, Chang SF, Way K and Kueh SL, 2008. Proposal for a fourth aquabirnavirus serogroup. *Archives of Virology*, 153, 1937–1941. <https://doi.org/10.1007/s00705-008-0192-9>
- Dixon PF, Algoët M, Bayley A, Dodge M, Joiner C and Roberts E, 2012a. Studies on the inactivation of selected viral and bacterial fish pathogens at high pH for waste disposal purposes. *Journal of Fish Diseases*, 35, 65–72. <https://doi.org/10.1111/j.1365-2761.2011.01316.x>
- Dixon PF, Smail DA, Algoët M, Hastings TS, Bayley A, Byrne H, Dodge M, Garden A, Joiner C, Roberts E, Verner-Jeffreys D and Thompson F, 2012b. Studies on the effect of temperature and pH on the inactivation of fish viral and bacterial pathogens. *Journal of Fish Diseases*, 35, 51–64. <https://doi.org/10.1111/j.1365-2761.2011.01324.x>
- Dopazo CP, 2020. The infectious pancreatic necrosis virus (IPNV) and its virulence determinants: what is known and what should be known. *Pathogens*, 9. <https://doi.org/10.3390/pathogens9020094>
- Dorson M and Touchy C, 1981. The influence of fish age and water temperature on mortalities of rainbow trout, *Salmo gairdneri* Richardson, caused by a European strain of infectious pancreatic necrosis virus. *Journal of Fish Diseases*, 4, 213–221. <https://doi.org/10.1111/j.1365-2761.1981.tb01128.x>
- Dorson M, 1982. Infectious pancreatic necrosis of Salmonids: present status of knowledge concerning the viruses and the possibilities of controlling the disease [strains of virus, serodiagnosis, symptoms of the disease, attempt at fish vaccination]. *Bulletin Francais de Pisciculture*, 54, 195–209. <https://doi.org/10.1051/kmae:1982010>
- Dorson M and Torchy C, 1985. Experimental transmission of infectious pancreatic necrosis virus via the sexual products. In: Ellis AE (ed.). *Fish and Shellfish Pathology*. Academic Press, London. pp. 251–260.
- Duan K, Zhao J, Ren G, Shao Y, Lu T, Xu L, Tang X, Zhao W and Xu L, 2021. Molecular evolution of infectious pancreatic necrosis virus in China. *Viruses*, 13. <https://doi.org/10.3390/v13030488>
- EFSA AHAW Panel, 2009. Species-specific welfare aspects of the main systems of stunning and killing of farmed Atlantic Salmon. *EFSA Journal* 2009;7(4):1011,77 pp.
- EFSA AHAW Panel, 2017a. Ad hoc method for the assessment on listing and categorisation of animal diseases within the framework of the Animal Health Law. *EFSA Journal*, 2017;15(7):4783,47 pp. <https://doi.org/10.2903/j.efsa.2017.4783>
- EFSA AHAW Panel, 2017b. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Koi herpes virus disease (KHV). *EFSA Journal* 2017;15(7):4907, 35 pp. <https://doi.org/10.2903/j.efsa.2017.4907>
- EFSA Scientific Committee, 2018. Guidance on uncertainty analysis in scientific assessments. Available online: <https://www.ncbi.nlm.nih.gov/pubmed/32625671>
- Eissler Y, Pavlov MS, Conejeros P, Espinoza JC and Kuznar J, 2011. Detection and quantification of Chilean strains of infectious pancreatic necrosis virus by real-time RT-PCR assays using segment b as a target. *Latin American Journal of Aquatic Research*, 39, 544–552. <https://doi.org/10.3856/vol39-issue3-fulltext-14>
- Erdal JI, Skjelstad B and Soleim KB, 2003. Presented at the Diseases of Fish and Shellfish 11th Conference of the EAAP, Malta 21–25 Sept 2003, O-103.
- Eriksson-Kallio AM, Holopainen R, Viljamaa-Dirks S, Vennerström P, Kuukka-Anttila H, Koski P and Gadd T, 2016. Infectious pancreatic necrosis virus (IPNV) strain with genetic properties associated with low pathogenicity at Finnish fish farms. *Diseases of Aquatic Organisms*, 118, 21–30. <https://doi.org/10.3354/dao02951>
- Eriksson-Kallio AM, 2022. Characteristics of Infectious Pancreatic Necrosis in Finland: Epidemiology, genetic characterization and virulence of infectious pancreatic necrosis virus (IPNV) of farmed fish in Finland. Available online: <http://hdl.handle.net/10138/342637>
- Escobar-Dodero J, Kinsley A, Perez AM, Ibarra R, Tello A, Monti G and Mardones FO, 2019. Risk factors for infectious pancreatic necrosis in farmed Chilean Atlantic salmon (*Salmo salar* L.) from 2010 to 2013. *Preventive Veterinary Medicine*, 167, 182–189. <https://doi.org/10.1016/j.prevetmed.2018.04.016>



- Eskildsen U and Jorgensen PV, 1973. On the possible transfer of trout pathogenic viruses by gulls. *Riv. Ital. Piscicoltura. Ittiopatol*, 8, 104–105.
- Evensen Ø and Santi N, 2008. Infectious pancreatic necrosis virus. In: Mahy BW and Van Regenmortel MH (eds.). *Encyclopedia of Virology*. Elsevier Ltd, Amsterdam. pp. 83–89.
- FHL and VESO (Norwegian Seafood Federation and VESO), 2003. IPN in salmonids a review; October 2003.
- Fisheries and Ocean Canada, 2017. Residual Infectious Pancreatic Necrosis (IPN) transmission risk from Arctic ahlar Transfers into British Columbia. Available online: <https://waves-vagues.dfo-mpo.gc.ca>
- Flores-Mara R, Rodríguez FH, Bangerla R, Lhorente JP, Neira R, Newman S and Yáñez JM, 2017. Resistance against infectious pancreatic necrosis exhibits significant genetic variation and is not genetically correlated with harvest weight in rainbow trout (*Oncorhynchus mykiss*). *Aquaculture*, 479, 155–160. <https://doi.org/10.1016/j.aquaculture.2017.05.042>
- Frantsi C and Savan M, 1971. Infectious pancreatic necrosis virus – temperature and age factors in mortality. *Wildlife Disease*, 7, 249–255. <https://doi.org/10.7589/0090-3558-7.4.249>
- Ghasemi M, Olesen NJ, Skall HF, Karsidani SH, Jonstrup SP, Zorriehzahra S, Sharifpour I, Soltani M and Sharifrohani M, 2011. Infectious pancreatic necrosis (IPN), a new threat of cultured rainbow trout in Iran. *Proceedings of the IMED 2011 International Meeting on Emerging Diseases and Surveillance*.
- Gibson D, Smail D and Sommerville C, 1998. Infectious pancreatic necrosis virus: experimental infection of goldsinny wrasse, *Ctenolabrus rupestris* L. (Labridae). *Journal of Fish Diseases*, 21, 399–406. <https://doi.org/10.1046/j.1365-2761.1998.00114>
- Gomez-Casado E, Estepa A and Coll JM, 2011. A comparative review on European-farmed finfish RNA viruses and their vaccines. *Vaccine*, 29, 2657–2671. <https://doi.org/10.1016/j.vaccine.2011.01.097>
- Graham D, 2006. Infectious pancreatic necrosis in farmed salmonids. Available online: <https://freshwater-aquaculture.extension.org/wp-content/uploads/2019/08/Add-fishinfectiouspancreaticnecrosis.pdf>
- Gräns A, Niklasson L, Sandblom E, Sundell K, Algers B, Berg C, Lundh T, Axelsson M, Sundh H and Kiessling A, 2016. Stunning fish with CO<sub>2</sub> or electricity: contradictory results on behavioural and physiological stress responses. *Animal*, 10, 294–301. <https://doi.org/10.1017/S1751731115000750>
- Guy DR, Bishop SC, Woolliams JA and Brotherstone S, 2009. Genetic parameters for resistance to infectious pancreatic necrosis in pedigreed Atlantic salmon (*Salmo salar*) post-smolts using a reduced animal model. *Aquaculture*, 290, 229–235. <https://doi.org/10.1016/j.aquaculture.2009.02.015>
- Guy DR, 2011. Genetic resistance to infectious pancreatic necrosis virus in pedigreed Atlantic salmon (*Salmo salar*) <https://doi.org/10.1016/j.aquaculture.2007.08.046>
- Halder M and Ahne W, 1988. Freshwater crayfish *Astacus astacus* – a vector for infectious pancreatic necrosis virus (IPNV). *Diseases of Aquatic Organisms*, 4, 205–209. <https://doi.org/10.3354/DAO004205>
- Hill B, 1982. Infectious pancreatic necrosis virus and its virulence. In: *Microbial Disease of Fish*. <https://doi.org/10.3390/pathogens9020094>
- Hill B and Way K, 1995. Serological classification of infectious pancreatic necrosis (IPN) virus and other aquatic birnaviruses. *Annual Review of Fish Diseases*, 5, 55–77. [https://doi.org/10.1016/0959-8030\(95\)00011-9](https://doi.org/10.1016/0959-8030(95)00011-9)
- Hillestad B, Johannessen S, Melingen GO and Moghadam HK, 2021. Identification of a new infectious pancreatic necrosis virus (IPNV) variant in Atlantic salmon (*Salmo salar* L.) that can cause high mortality even in genetically resistant fish. *Frontiers in Genetics*, 12, 635185. <https://doi.org/10.3389/fgene.2021.635185>
- Houston RD, Gheyas A, Hamilton A, Guy DR, Tinch AE, Taggart JB, McAndrew BJ, Haley CS and Bishop SC, 2008. Detection and confirmation of a major QTL affecting resistance to infectious pancreatic necrosis (IPN) in Atlantic salmon (*Salmo salar*). *Developments in Biologicals*, 132, 199–204. <https://doi.org/10.1159/000317160>
- Houston RD, Haley CS, Hamilton A, Guy DR, Mota-Velasco JC, Gheyas AA, Tinch AE, Taggart J, Bron J and Starkey W, 2010. The susceptibility of Atlantic salmon fry to freshwater infectious pancreatic necrosis is largely explained by a major QTL. *Heredity*, 105, 318–327. <https://doi.org/10.1038/hdy.2009.171>
- Hudson E, Bucke D and Forrest A, 1981. Isolation of infectious pancreatic necrosis virus from eels, *Anguilla anguilla* L., in the United Kingdom. *Journal of Fish Diseases*, 4, 429–431.
- Jarp J, Gjevne A, Olsen A and Bruheim T, 1995. Risk factors for furunculosis, infectious pancreatic necrosis and mortality in post-smolt of Atlantic salmon, *Salmo solar* L. *Journal of Fish Diseases*, 18, 67–78. <https://doi.org/10.1111/j.1365-2761.1995.tb01267.x>
- Jensen I, Seppola M, Steiro K, Sandaker E, Mennen S and Sommer AI, 2009. Susceptibility of Atlantic cod *Gadus morhua* juveniles to different routes of experimental challenge with infectious pancreatic necrosis virus (IPNV). *Diseases of Aquatic Organisms*, 85, 105–113. <https://doi.org/10.3354/dao02066>
- Jeon CH, Kim SR, Kim WS, Lee CH, Seong KB, Lee CS, Oh MJ and Kim JH, 2011. Monitoring of viruses in chum salmon (*Oncorhynchus keta*) migrating to Korea. *Archives of Virology*, 156, 1025–1030. <https://doi.org/10.1007/s00705-011-0944-9>
- Johnson SC, Bravo S, Nagasawa K, Kabata Z, Hwang J, Ho J and Shih C, 2004. A review of the impact of parasitic copepods on marine aquaculture. *Zoological Studies*, 43, 229–243.
- Jung S-J, Kitamura S-I, Kawai K and Suzuki S, 1999. Isolation of different types of birnavirus from ayu *Plecoglossus altivelis* and amago salmon *Oncorhynchus rhodurus* cultured in the same geographic area. *Diseases of Aquatic Organisms*, 38, 87–91.

- Kim WS and Oh MJ, 2014. Genetic positioning of aquabirnavirus isolates from cultured Japanese eel *Anguilla japonica* in Korea. *Diseases of Aquatic Organisms*, 109, 9–14. <https://doi.org/10.3354/dao02724>
- Kusuda R, Nishi Y, Hosono N and Suzuki S, 1993. Serological comparison of birnaviruses isolated from several species of marine fish in South West Japan. *Fish Pathology*, 28, 91–92. <https://doi.org/10.3147/jsfp.28.91>
- Laidler L, 2002. Atlantic salmon broodstock and vertical transmission of infectious pancreatic necrosis virus. Available online: <https://www.fishvetsociety.org.uk>
- Lopez-Jimena B, Garcia-Rosado E, Infante C, Cano I, Manchado M, Castro D, Borrego JJ and Alonso MC, 2010. Detection of infectious pancreatic necrosis virus (IPNV) from asymptomatic redbanded seabream, *Pagrus auriga* Valenciennes, and common seabream, *Pagrus pagrus* (L.), using a non-destructive procedure. *Journal of Fish Diseases*, 33, 311–319. <https://doi.org/10.1111/j.1365-2761.2009.01123.x>
- Lopez-Lastra M, Gonzalez M, Jashes M and Sandino A, 1994. A detection method for infectious pancreatic necrosis virus (IPNV) based on reverse transcription (RT)-polymerase chain reaction (PCR). *Journal of Fish Diseases*, 17, 269–282. <https://doi.org/10.1111/j.1365-2761.1994.tb00222.x>
- Lorenzen E, Olesen NJ, Evensen Ø and Strum A, 1995. Outbreaks of IPN in reared fry of Atlantic cod *Gadus morhua*. In *Proceedings of the 7th International Conference on Diseases of Fish and Shellfish*, Palma de Mallorca, Spain.
- Ma J, Bruce TJ, Jones EM and Cain KD, 2019a. A review of fish vaccine development strategies: conventional methods and modern biotechnological approaches. *Microorganisms*, 7, 569. <https://doi.org/10.3390/microorganisms7110569>
- Ma J, Chen R, Huang W, Nie J, Liu Q, Wang Y and Yang X, 2019b. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. *Human Vaccines & Immunotherapeutics*, 15, 1–9. <https://doi.org/10.1080/21645515.2019.1627820>
- Maheshkumar S, Goyal SM, Peterson RB and Economon PP, 1991. Method for the concentration of infectious pancreatic necrosis virus from hatchery water. *Journal of Virological Methods*, 31, 211–217. [https://doi.org/10.1016/0166-0934\(91\)90159-w](https://doi.org/10.1016/0166-0934(91)90159-w)
- Maj-Paluch J, Matras M, Borzym E, Stachnik M and Reichert M, 2020. Phylogenetic characterization of Polish isolates of infectious pancreatic necrosis virus in salmonid fish. *Journal of Fish Diseases*, 43, 1443–1451. <https://doi.org/10.1111/jfd.13249>
- Mangunwiryo H and Agius C, 1988. Studies on the carrier state of infectious pancreatic necrosis virus infections in rainbow trout, *Salmo gairdneri* Richardson. *Journal of Fish Diseases*, 11, 125–132. <https://doi.org/10.1111/j.1365-2761.1988.tb00532.x>
- Maria Poli B, 2009. Farmed fish welfare-suffering assessment and impact on product quality. *Italian Journal of Animal Science*, 8, 139–160. <https://doi.org/10.4081/ijas.2009.s1.139>
- McAllister PE, 1983. Infectious pancreatic necrosis (IPN) of salmonid fishes. Available online: <https://www.usgs.gov>
- McAllister PE and Owens WJ, 1992. Recovery of infectious pancreatic necrosis virus from the faeces of wild piscivorous birds. *Aquaculture*, 106, 227–232. [https://doi.org/10.1016/0044-8486\(92\)90254-I](https://doi.org/10.1016/0044-8486(92)90254-I)
- McAllister PE, 2007. Infectious pancreatic necrosis FS-FHS (American Fisheries Society-Fish Health Section), FHS Blue Book: Suggested Procedures for the Detection and Identification of Certain Finfish and Shellfish Pathogens.
- McLoughlin M and Weigall B, 2002. Infectious pancreatic necrosis (IPN) of Atlantic salmon: summary of FVS seminar June 2000. Available online: <https://www.fishvetsociety.org.uk>
- Melby H, Krogsrud J, Håstein T and Stenwig H, 1991. All commercial Atlantic salmon seawater farms in Norway harbour carriers of infectious pancreatic necrosis virus (IPNV). *Proceedings of the Proceedings from the 2nd international symposium on viruses of lower vertebrates*, pp. 211–217.
- Mikalsen AB, Torgersen J, Aleström P, Hellemann AL, Koppang EO and Rimstad E, 2004. Protection of atlantic salmon *Salmo salar* against infectious pancreatic necrosis after DNA vaccination. *Diseases of Aquatic Organisms*, 60, 11–20. <https://doi.org/10.3354/dao060011>
- Moen T, Baranski M, Sonesson AK and Kjølglum S, 2009. Confirmation and fine-mapping of a major QTL for resistance to infectious pancreatic necrosis in Atlantic salmon (*Salmo salar*): population-level associations between markers and trait. *BMC Genomics*, 10, 368. <https://doi.org/10.1186/1471-2164-10-368>
- Moen T, Torgersen J, Santi N, Davidson WS, Baranski M, Ødegård J, Kjølglum S, Velle B, Kent M and Lubieniecki KP, 2015. Epithelial cadherin determines resistance to infectious pancreatic necrosis virus in Atlantic salmon. *Genetics*, 200, 1313–1326. <https://doi.org/10.1534/genetics.115.175406>
- Moewus-Kobb L, 1965. Studies with IPN virus in marine hosts. *Annals of the New York Academy of Sciences*, 126, 328–342. <https://doi.org/10.1111/j.1749-6632.1965.tb14284.x>
- Molloy SD, Pietrak MR, Bricknell I and Bouchard DA, 2013. Experimental transmission of infectious pancreatic necrosis virus from the blue mussel, *Mytilus edulis*, to cohabitating Atlantic Salmon (*Salmo salar*) smolts. *Applied and Environmental Microbiology*, 79, 5882–5890. <https://doi.org/10.1128/aem.01142-13>
- Moreno P, Oliveira JG, Labella A, Cutrín JM, Baro JC, Borrego JJ and Dopazo CP, 2014. Surveillance of viruses in wild fish populations in areas around the Gulf of Cadiz (South Atlantic Iberian Peninsula). *Applied and Environmental Microbiology*, 80, 6560–6571. <https://doi.org/10.1128/aem.02090-14>

- Mortensen SH, Evensen Ø, Rødseth OM and Hjeltnes BK, 1993. The relevance of infectious pancreatic necrosis virus (IPNV) in farmed Norwegian turbot (*Scophthalmus maximus*). *Aquaculture*, 115, 243–252. [https://doi.org/10.1016/0044-8486\(93\)90140-T](https://doi.org/10.1016/0044-8486(93)90140-T)
- Mulei I, Nyaga P, Muthia P, Waruiru R, Njagi L, Mwiha E, Gamil A, Evensen Ø and Mutoloki S, 2018. Infectious pancreatic necrosis virus isolated from farmed rainbow trout and tilapia in Kenya is identical to European isolates. *Journal of Fish Diseases*, 41, 1191–1200.
- Munang'andu HM, Fredriksen BN, Mutoloki S, Brudeseth B, Kuo TY, Marjara IS, Dalmo RA and Evensen Ø, 2012. Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L.) in a cohabitation challenge model. *Vaccine*, 30, 4007–4016. <https://doi.org/10.1016/j.vaccine.2012.04.039>
- Munang'andu HM, Mutoloki S and Evensen O, 2016. Birnaviruses of aquatic organisms. In: Kibenge FSB and Godoy MG (eds.). *Aquaculture Virology*. Academic Press, London. pp. 237–250.
- Munang'andu HM and Evensen Ø, 2015. A review of intra-and extracellular antigen delivery systems for virus vaccines of finfish. *Journal of Immunology Research*, 2015, 960859. <https://doi.org/10.1155/2015/960859>
- Munro A, Liversidge J and Elson K, 1976. The distribution and prevalence of infectious pancreatic necrosis virus in wild fish in Loch Awe. *Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences*, 75, 223–232. <https://doi.org/10.1017/S030821130000267X>
- Munro E, Gahlawat S and Ellis A, 2004. A sensitive non-destructive method for detecting IPNV carrier Atlantic salmon, *Salmo salar* L., by culture of virus from plastic adherent blood leucocytes. *Journal of Fish Diseases*, 27, 129–134. <https://doi.org/10.1111/j.1365-2761.2004.00520.x>
- Munro ES, Millar CP and Hastings TS, 2010. An analysis of levels of infectious pancreatic necrosis virus in Atlantic salmon, *Salmo salar* L., broodstock in Scotland between 1990–2002. *Journal of Fish Diseases*, 33, 171–177. <https://doi.org/10.1111/j.1365-2761.2009.01114.x>
- Munro ES and Midtlyng PJ, 2011. Infectious pancreatic necrosis and associated aquatic birnaviruses. *Fish Diseases and Disorders*, 3, 1–65. <https://doi.org/10.1079/9781845935542.000>
- Murray AG, Busby CD and Bruno DW, 2003. Infectious pancreatic necrosis virus in Scottish Atlantic salmon farms, 1996–2001. *Emerging Infectious Diseases*, 9, 455–460. <https://doi.org/10.3201/eid0904.020311>
- Murray AG, Leschen WA, Kilburn R and Raynard RS, 2004. A case-control study for the identification of risk factors behind clinical outbreaks of infectious pancreatic necrosis (IPN). Available online: <https://www.gov.scot>
- Murray AG, 2006. A model of the emergence of infectious pancreatic necrosis virus in Scottish salmon farms 1996–2003. *Ecological Modelling*, 199, 64–72. <https://doi.org/10.1016/j.ecolmodel.2006.06.010>
- Mutoloki S, Jøssund TB, Ritchie G, Munang'andu HM and Evensen Ø, 2016. Infectious pancreatic necrosis virus causing clinical and subclinical infections in Atlantic salmon have different genetic fingerprints. *Frontiers in Microbiology*, 7, 1393. <https://doi.org/10.3389/fmicb.2016.01393>
- Nicholson BL and Caswell P, 1982. Enzyme-linked immunosorbent assay for identification of infectious pancreatic necrosis virus. *Journal of Clinical Microbiology*, 16, 469–472. <https://doi.org/10.1128/jcm.16.3.469-472.1982>
- Nishizawa T, Kinoshita S and Yoshimizu M, 2005. An approach for genogrouping of Japanese isolates of aquabirnaviruses in a new genogroup, VII, based on the VP2/NS junction region. *The Journal of General Virology*, 86, 1973–1978. <https://doi.org/10.1099/vir.0.80438-0>
- Nobiron I, Galloux M, Henry C, Torhy C, Boudinot P, Lejal N, Da Costa B and Delmas B, 2008. Genome and polypeptides characterization of Tellina virus 1 reveals a fifth genetic cluster in the Birnaviridae family. *Virology*, 371, 350–361. <https://doi.org/10.1016/j.virol.2007.09.022>
- Norwegian Biotechnology Advisory Board, 2020. Norwegian consumers' attitudes toward gene editing in Norwegian agriculture and aquaculture. Available online: <https://epsoweb.org/uncategorized/norwegian-consumers-attitudes-toward-gene-editing-in-norwegian-agriculture-and-aquaculture-other-countries-should-follow/2020/04/17/>
- Novoa B, Huerta AF, Puentes CF, Ledo A and Toranzo AE, 1993. Characterization of a birnavirus isolated from diseased turbot cultured in Spain.
- Ogut H and Altuntas C, 2012. Occurrence and prevalence of infectious pancreatic necrosis virus in rainbow trout (*Oncorhynchus mykiss*) cultured in cages in the Black Sea. *Aquaculture Research*, 43, 1550–1556. <https://doi.org/10.1111/J.1365-2109.2011.02959.X>
- Ogut H, Altuntas C and Parlak R, 2013. Viral surveillance of cultured Rainbow Trout in the eastern Black Sea, Turkey. *Journal of Aquatic Animal Health*, 25, 27–35. <https://doi.org/10.1080/08997659.2012.732652>
- Oidtmann B, Dixon P, Way K, Joiner C and Bayley AE, 2018. Risk of waterborne virus spread—review of survival of relevant fish and crustacean viruses in the aquatic environment and implications for control measures. *Reviews in Aquaculture*, 10, 641–669. <https://doi.org/10.1111/raq.12192>
- Ortega C, 1993. Epidemiological risk factors affecting the presentation of viral agents in freshwater aquaculture in northeastern Spain. *Bulletin of the European Association of Fish Pathologists*, 13, 154.
- Ortega C, Valladares B, Arguedas D, Vega F, Montes de Oca R and Murray AG, 2016. Distribution of infectious pancreatic necrosis virus (IPNV) based on surveillance programs in freshwater trout farms of Mexico. *Journal of Aquatic Animal Health*, 28, 21–26. <https://doi.org/10.1080/08997659.2015.1131757>
- Overstreet RM, Jovonovich J and Ma H, 2009. Parasitic crustaceans as vectors of viruses, with an emphasis on three penaeid viruses. *Integrative and Comparative Biology*, 49, 127–141. <https://doi.org/10.1093/icb/icp033>



- Panzarin V, Holmes EC, Abbadi M, Zamperin G, Quartesan R, Milani A, Schivo A, Bille L, Dalla Pozza M, Monne I and Toffan A, 2018. Low evolutionary rate of infectious pancreatic necrosis virus (IPNV) in Italy is associated with reduced virulence in trout. *Virus Evolution*, 4, vey019. <https://doi.org/10.1093/ve/vey019>
- Pavelin J, Jin YH, Gratacap RL, Taggart JB, Hamilton A, Verner-Jeffreys DW, Paley RK, Rubin CJ, Bishop SC, Bron JE, Robledo D and Houston RD, 2021. The nedd-8 activating enzyme gene underlies genetic resistance to infectious pancreatic necrosis virus in Atlantic salmon. *Genomics*, 113, 3842–3850. <https://doi.org/10.1016/j.ygeno.2021.09.012>
- Persson BD, Schmidt JG, Hakhverdyan M, Leijon M, Olesen NJ and Axén C, 2023. Characterization of a Novel Infectious Pancreatic Necrosis Virus (IPNV) from Genogroup 6 Identified in Sea Trout (*Salmo trutta*) from Lake Vänern, Sweden. *Veterinary Medicine*, 10. <https://doi.org/10.3390/vetsci10010058>
- Peters F and Neukirch M, 1986. Transmission of some fish pathogenic viruses by the heron, *Ardea cinerea*. *Journal of Fish Diseases*, 9, 539–544. <https://doi.org/10.1111/j.1365-2761.1986.tb01050.x>
- Research Excellence Framework, 2021. Impact case study: Genomics-enabled breeding for disease resistance prevents mortality and improves welfare in aquaculture. Available online: [https://www.ed.ac.uk/sites/default/files/atoms/files/impact\\_pages\\_ref\\_case\\_study\\_-\\_salmon\\_genetics.pdf](https://www.ed.ac.uk/sites/default/files/atoms/files/impact_pages_ref_case_study_-_salmon_genetics.pdf)
- Rexhepi A, Bërholi K, Scheinert P, Hamidi A and Sherifi K, 2011. Study of viral diseases in some freshwater fish in the Republic of Kosovo. *Veterinarski Arhiv*, 81, 405–413. Available online: <https://hrcak.srce.hr/69495>
- Rexhepi A, Sherifi K, Scheinert P and Grapci-Kotorri L, 2014. The occurrence and prevention of infectious pancreatic necrosis virus (IPNV) in rainbow trout fish farms: the importance of improved sanitary practices. *Albanian Journal of Agricultural Sciences*, 13, 33.
- Riji John K and Richards RH, 1999. Characteristics of a new birnavirus associated with a warm-water fish cell line. *The Journal of General Virology*, 80(Pt 8), 2061–2065. <https://doi.org/10.1099/0022-1317-80-8-2061>
- Rimsta E, 2019, online. Infectious pancreatic necrosis. Available online: <https://www.cabi.org/isc/datasheet/79273#tohostAnimals>
- Rimstad E, 2014. Vaccination against infectious pancreatic necrosis. In: Gudding R, Lillehaug A and Evensen Ø (eds.). *Fish Vaccination*. Wiley Blackwell, Chichester. pp. 303–312.
- Rivas C, Cepeda C, Dopazo CP, Novoa B, Noya M and Barja JL, 1993. Marine environment as reservoir of birnaviruses from poikilothermic animals. *Aquaculture*, 115, 183–194. [https://doi.org/10.1016/0044-8486\(93\)90135-L](https://doi.org/10.1016/0044-8486(93)90135-L)
- Rodger H and Frerichs G, 1997. Clinical infectious pancreatic necrosis virus infection in farmed halibut in the United Kingdom. *The Veterinary Record*, 140, 401–402. <https://doi.org/10.1136/vr.140.15.401>
- Roberts RJ and Pearson MD, 2005. Infectious pancreatic necrosis in Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases*, 28, 383–390. <https://doi.org/10.1111/j.1365-2761.2005.00642.x>
- Rodríguez S, Vilas MP, Gutierrez MC, Pérez-Prieto SI, Sarasquete MC and Rodríguez RB, 1997. Isolation and preliminary characterization of a birnavirus from the sole *Solea senegalensis* in Southwest Spain. *Journal of Aquatic Animal Health*, 9, 295–300. [https://doi.org/10.1577/1548-8667\(1997\)009<0295:IAPCOA>2.3.CO;2](https://doi.org/10.1577/1548-8667(1997)009<0295:IAPCOA>2.3.CO;2)
- Rodríguez FH, Flores-Mara R, Yoshida GM, Barría A, Jedlicki AM, Lhorente JP, Reyes-López F and Yáñez JM, 2019. Genome-wide association analysis for resistance to infectious pancreatic necrosis virus identifies candidate genes involved in viral replication and immune response in rainbow trout (*Oncorhynchus mykiss*). *G3: Genes, Genomes, Genetics*, 9, 2897–2904. <https://doi.org/10.1534/g3.119.400463>
- Rodriguez Saint-Jean S, Borrego JJ and Perez-Prieto SI, 2001. Comparative evaluation of five serological methods and RT-PCR assay for the detection of IPNV in fish. *Journal of Virological Methods*, 97, 23–31. [https://doi.org/10.1016/s0166-0934\(01\)00329-9](https://doi.org/10.1016/s0166-0934(01)00329-9)
- Rodriguez Saint-Jean S, Borrego JJ and Perez-Prieto SI, 2003. Infectious pancreatic necrosis virus: biology, pathogenesis, and diagnostic methods. *Advances in Virus Research*, 62, 113–165. [https://doi.org/10.1016/s0065-3527\(03\)62003-8](https://doi.org/10.1016/s0065-3527(03)62003-8)
- Ruane N, Geoghegan F and Ó Cinneide M, 2007. Infectious pancreatic necrosis virus and its impact on the Irish salmon aquaculture and wild fish sectors. 1649-0053. Available online: <https://oar.marine.ie>
- Rud YP, Maistrenko M, Zaloilo O, Liubchenko G, Buchatskiy L and Hrytsyniak I, 2020. Experimental infection of brown trout (*Salmo trutta*), zebrafish (*Danio rerio*), and swan mussel (*Anodonta cygnea*) with infectious pancreatic necrosis virus (IPNV). *Agricultural Science and Practice*, 7, 31–40. Available online: <https://www.agrisp.com>
- Sadasiv EC, 1995. Immunological and pathological responses of salmonids to infectious pancreatic necrosis virus (IPNV). *Annual Review of Fish Diseases*, 5, 209–223. [https://doi.org/10.1016/0959-8030\(95\)00001-1](https://doi.org/10.1016/0959-8030(95)00001-1)
- Sanger F, Nicklen S and Coulson AR, 1977. DNA sequencing with chain-terminating inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, 74, 5463–5467.
- Schutz M, May E, Kraeuter J and Hetrick F, 1984. Isolation of infectious pancreatic necrosis virus from an epizootic occurring in cultured striped bass, *Morone saxatilis* (Walbaum). *Journal of Fish Diseases*, 7, 505–507. <https://doi.org/10.1111/j.1365-2761.1984.tb01176.x>
- Scottish Government, 2019, online. Diseases of wild and farmed finfish.
- Shivappa RB, Song H, Yao K, Aas-Eng A, Evensen O and Vakharia VN, 2004. Molecular characterization of Sp serotype strains of infectious pancreatic necrosis virus exhibiting differences in virulence. *Diseases of Aquatic Organisms*, 61, 23–32. <https://doi.org/10.3354/dao061023>

- Smail D, Huntly P and Munro A, 1993a. Fate of four fish pathogens after exposure to fish silage containing fish farm mortalities and conditions for the inactivation of infectious pancreatic necrosis virus. *Aquaculture*, 113, 173–181. [https://doi.org/10.1016/0044-8486\(93\)90471-A](https://doi.org/10.1016/0044-8486(93)90471-A)
- Smail DA, Irwin N, Harrison D and Munro ALS, 1993b. Passage and survival of infectious pancreatic necrosis (IPN) virus in the cow's gut after feeding a silage mixture containing IPN virus. *Aquaculture*, 113, 183–187. [https://doi.org/10.1016/0044-8486\(93\)90472-B](https://doi.org/10.1016/0044-8486(93)90472-B)
- Smail DA, Bain N, Bruno DW, King JA, Thompson F, Pendrey DJ, Morrice S and Cunningham CO, 2006. Infectious pancreatic necrosis virus in Atlantic salmon, *Salmo salar* L., post-smolts in the Shetland Isles, Scotland: virus identification, histopathology, immunohistochemistry and genetic comparison with Scottish mainland isolates. *Journal of Fish Diseases*, 29, 31–41. <https://doi.org/10.1111/j.1365-2761.2005.00678.x>
- Smail D and Munro E, 2012. *The Virology of Teleosts*. W.B. Saunders, London.
- Smith G, Bebak J and McAllister PE, 2000. Experimental infectious pancreatic necrosis infections: propagative or point-source epidemic? *Preventive Veterinary Medicine*, 47, 221–241. [https://doi.org/10.1016/S0167-5877\(00\)00176-8](https://doi.org/10.1016/S0167-5877(00)00176-8)
- Sommer A-I, Strand MA, Rasmussen E and Mennen S, 2004. Susceptibility of spotted wolffish *Anarhichas minor* to experimental infection with nodavirus and infectious pancreatic necrosis virus. *Diseases of Aquatic Organisms*, 59, 101–108. <https://doi.org/10.3354/dao059101>
- Sommerset I, Walde C, Bang Jensen B, Bornø B, Haukaas A and Brun E, 2020. Fiskehelseberapporten 2019. Available online: <https://www.vetinst.no>
- Sommerset I, Walde C, Bang Jensen B, Wiik-Nielsen J, Bornø G, Oliveira VHS and HAaB E, 2022. Norwegian fish health report 2021. Norwegian Veterinary Institute Report. Available online: <https://www.vetinst.no>
- Sonstegard RA and McDermott LA, 1972. Epidemiological model for passive transfer of IPNV by homeotherms. *Nature*, 237, 104–105. <https://doi.org/10.1038/237104a0>
- Sorimachi M and Hara T, 1985. Characteristics and pathogenicity of a virus isolated from yellowtail fingerlings showing ascites. *Fish Pathology*, 19, 231–238. <https://doi.org/10.3147/jsfp.19.231>
- Stephens EB, Newman MW, Zachary AL and Hetrick FM, 1980. A viral aetiology for the annual spring epizootics of Atlantic menhaden *Brevoortia tyrannus* (Latrobe) in Chesapeake Bay. *Journal of Fish Diseases*, 3, 387–398. <https://doi.org/10.1111/j.1365-2761.1980.tb00423.x>
- Storset A, Strand C, Wetten M, Kjøglum S and Ramstad A, 2007. Response to selection for resistance against infectious pancreatic necrosis in Atlantic salmon (*Salmo salar* L.). *Aquaculture*, 272, S62–S68.
- SVA National Veterinary Institute, 2020. Surveillance of infectious diseases in animals and humans in Sweden 2020. Available online: <https://www.sva.se>
- Tapia D, Eissler Y, Torres P, Jorquera E, Espinoza JC and Kuznar J, 2015. Detection and phylogenetic analysis of infectious pancreatic necrosis virus in Chile. *Diseases of Aquatic Organisms*, 116, 173–184. <https://doi.org/10.3354/dao02912>
- Tapia D, Eissler Y, Reyes-Lopez FE, Kuznar J and Yáñez JM, 2022. Infectious pancreatic necrosis virus in salmonids: Molecular epidemiology and host response to infection. *Reviews in Aquaculture*, 14, 751–769. <https://doi.org/10.1111/raq.12623>
- Toranzo A and Hetrick F, 1982. Comparative stability of two salmonid viruses pancreatic necrosis and haematopoietic necrosis viruses and poliovirus in fresh, estuarine and marine waters. *Journal of Fish Diseases*, 5, 223–231. <https://doi.org/10.1111/j.1365-2761.1982.tb00477.x>
- Tu KC, Spendlove RS and Goede RW, 1975. Effect of temperature on survival and growth of infectious pancreatic necrosis virus. *Infection and Immunity*, 11, 1409–1412. <https://doi.org/10.1128/iai.11.6.1409-1412.1975>
- Ulrich K, Wehner S, Bekaert M, Di Paola N, Dilcher M, Muir KF, Taggart JB, Matejusova I and Weidmann M, 2018. Molecular epidemiological study on infectious pancreatic necrosis virus isolates from aquafarms in Scotland over three decades. *The Journal of General Virology*, 99, 1567–1581. <https://doi.org/10.1099/jgv.0.001155>
- Urquhart K, Murray AG, Gregory A, O'Dea M, Munro LA, Smail DA, Shanks AM and Raynard RS, 2008. Estimation of infectious dose and viral shedding rates for infectious pancreatic necrosis virus in Atlantic salmon, *Salmo salar* L., post-smolts. *Journal of Fish Diseases*, 31, 879–887. <https://doi.org/10.1111/j.1365-2761.2008.00989.x>
- Urquhart K, Bowden TJ, Buckett BE, Garcia J, Fryer RJ and Ellis AE, 2009. Experimental study of the susceptibility of Atlantic cod, *Gadus morhua* (L.), to infection with an IPNV strain pathogenic for Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases*, 32, 447–456. <https://doi.org/10.1111/j.1365-2761.2009.01036.x>
- Varvarigos P and Way K, 2002. First isolation and identification of the Infectious Pancreatic Necrosis (IPN) virus from rainbow trout *Onchorhynchus mykiss* fingerlings farmed in Greece. pp. 195–200. Available online: <https://eafp.org/>
- Wallace I, Gregory A, Munro E, Bain N and Raynard R, 2005. Infectious pancreatic necrosis virus isolated from hake, *Merluccius merluccius*, from Scotland. *Bulletin of the European Association of Fish Pathologists*, 25, 86.
- Wallace IS, Gregory A, Murray AG, Munro ES and Raynard RS, 2008. Distribution of infectious pancreatic necrosis virus (IPNV) in wild marine fish from Scottish waters with respect to clinically infected aquaculture sites producing Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases*, 31, 177–186. <https://doi.org/10.1111/j.1365-2761.2007.00886.x>
- Wattanavijarn W, Torchy C, Tangtronpiros J and De Kinkelin P, 1988. Isolation of a birnavirus belonging to Sp serotype, from Southeast Asia fishes. *Bulletin of the European Association of Fish Pathologists*, 8, 106.




- WOAH, 2022. Aquatic code: chapter 7.4. Killing of farmed fish for disease control purposes. Available online: <https://www.woah.org/en/what-we-do/standards/codes-and-manuals/aquatic-code-online-access/>
- Wolf K, Quimby M and Bradford AD, 1963. Egg-associated transmission of IPN virus of trouts. *Virology*, 21, 317–321. [https://doi.org/10.1016/0042-6822\(63\)90192-2](https://doi.org/10.1016/0042-6822(63)90192-2)
- Wolf K and Quimby M, 1969. Infectious pancreatic necrosis: clinical and immune response of adult trouts to inoculation with live virus. *Journal of the Fisheries Board of Canada*, 26, 2511–2516. <https://doi.org/10.1139/F69-241>
- Wolf K, 1988. *Fish Viruses and Fish Viral Diseases*. Cornell University Press, Ithaca, NY.
- Woo PT, Leong J-A and Buchmann K, 2020. *Climate Change and Infectious Fish Diseases*. CABI, Boston, MA.
- Yamamoto T, 1974. Infectious pancreatic necrosis virus occurrence at a hatchery in Alberta. *Journal of the Fisheries Board of Canada*, 31, 397–402. <https://doi.org/10.1139/F74-067>
- Zhang CX and Suzuki S, 2003. Comparison of the RNA polymerase genes of marine birnavirus strains and other birnaviruses. *Archives of Virology*, 148, 745–758. <https://doi.org/10.1007/s00705-002-0951-y>
- Zhu L, Wang X, Wang K, Yang Q, He J, Qin Z, Geng Y, Ouyang P and Huang X, 2017. Outbreak of infectious pancreatic necrosis virus (IPNV) in farmed rainbow trout in China. *Acta Tropica*, 170, 63–69. <https://doi.org/10.1016/j.actatropica.2017.02.025>


## Abbreviations

AHAW	Animal Health and Welfare
AHL	Animal Health Law
CI	current impact
IPN	infectious pancreatic necrosis
IPNV	infectious pancreatic necrosis virus
MS	Member State
MSs	Member States
OIE	Office International des Épizooties (World Organisation For Animal Health)
PCR	polymerase chain reaction
PI	potential impact
QTL	quantitative trait loci
Se	sensitivity
Sp	specificity
ToR	terms of reference
WOAH	World Organisation for Animal Health


## Appendix A – Expert judgement plotted by question




**Figure A.1:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion A(i) (the disease is transmissible). Black dotted line on the top indicates the median



**Figure A.2:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion A (ii) (animal species are either susceptible to the disease or vectors and reservoirs thereof exist in the Union). Black dotted line on the top indicates the median




**Figure A.3:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion A(iii) (the disease causes negative effects on animal health or poses a risk to public health due to its zoonotic character). Black dotted line on the top indicates the median



**Figure A.4:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion A(iv) (diagnostic tools are available for the disease). Black dotted line on the top indicates the median






**Figure A.5:** Individual probability ranges, after the collective judgement, reflecting uncertain outcome on criterion A(v) (risk-mitigating measures and, where relevant, surveillance of the disease are effective and proportionate to the risks posed by the disease in the Union). Black dotted line on the top indicates the median








**Figure A.8:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion B(iv) (the disease has the potential to generate a crisis, or the disease agent could be used for the purpose of bioterrorism). Black dotted line on the top indicates the median









**Figure A.10:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 1A (the disease is not present in the territory of the Union or present only in exceptional cases (irregular introductions) or present in only a very limited part of the territory of the Union). Black dotted line on the top indicates the median






**Figure A.12:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion 1Caqua (the disease is present in the whole or part of the Union territory with an endemic character). Black dotted line on the top indicates the median






**Figure A.14:** Individual probability ranges, after the collective judgement, reflecting the fulfilment of criterion 2.1BC (the disease is moderately to highly transmissible). Black dotted line on the top indicates the median






**Figure A.15:** Individual probability ranges, after the collective judgement, reflecting the fulfilment of criterion 2.2AB (there are possibilities of airborne or waterborne or vector-borne spread). Black dotted line on the top indicates the median



**Figure A.16:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion 2.3A (the disease affects multiple species of kept and wild animals or single species of kept animals of economic importance). Black dotted line on the top indicates the median









**Figure A.19:** Individual probability ranges, after the collective judgement, reflecting fulfilment of criterion 2.4Caqua (the disease usually does not result in high morbidity and has negligible or no mortality and often the most observed effect of the disease is production loss). Black dotted line on the top indicates the median






**Figure A.20:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 3ABC (the disease has a zoonotic potential with significant consequences for public health or possible significant threats to food safety). Black dotted line on the top indicates the median




**Figure A.21:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 3AB (the disease has a zoonotic potential with significant consequences for public health, including epidemic potential or possible significant threats to food safety). Black dotted line on the top indicates the median




**Figure A.22:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 3A (the disease has a zoonotic potential with significant consequences for public health, including epidemic or pandemic potential or possible significant threats to food safety). Black dotted line on the top indicates the median






**Figure A.24:** Individual probability ranges, after the collective judgement, reflecting uncertainty on criterion 4AB (potential impact) (the disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals). Black dotted line on the top indicates the median







**Figure A.25:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 4C (current impact) (the disease has a significant impact on the economy of the Union, mainly related to its direct impact on certain types of animal production systems). Black dotted line on the top indicates the median




**Figure A.26:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 4C (potential impact) (the disease has a significant impact on the economy of the Union, mainly related to its direct impact on certain types of animal production systems). Black dotted line on the top indicates the median



**Figure A.27:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 5(a) (current impact) (the disease has a significant impact on society, with in particular an impact on labour markets). Black dotted line on the top indicates the median




**Figure A.28:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 5(a) (potential impact) (the disease has a significant impact on society, with in particular an impact on labour markets). Black dotted line on the top indicates the median



**Figure A.29:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 5(b) (current impact) (the disease has a significant impact on animal welfare, by causing suffering of large numbers of animals). Black dotted line on the top indicates the median






**Figure A.30:** Individual probability ranges, after the collective judgement, reflecting uncertain outcome on criterion 5(b) (potential impact) (the disease has a significant impact on animal welfare, by causing suffering of large numbers of animals). Black dotted line on the top indicates the median










**Figure A.34:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion 5(d) (potential impact) (the disease has a significant impact in the long term on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds). Black dotted line on the top indicates the median



**Figure A.35:** Individual probability ranges, after the collective judgement, reflecting non-fulfilment of criterion D (the risk posed by the disease can be effectively and proportionately mitigated by measures concerning movements of animals and products in order to prevent or limit its occurrence and spread). Black dotted line on the top indicates the median



Appendix B – Expert judgement: medians for all questions




Figure B.1: Medians of the judgement replies in questions related to article 5 (left side) and article 9 (right side)